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SUMMARY
TheWnt pathway is abnormally activated in themajor-
ity of colorectal cancers, and significant knowledge
has been gained in understanding its role in tumor
initiation. However, the mechanisms of metastatic
outgrowth in colorectal cancer remain a major chal-
lenge. We report that autophagy-dependent meta-
bolic adaptation and survival of metastatic colorectal
cancer cells is regulated by the target of oncoge-
nic Wnt signaling, homeobox transcription factor
PROX1, expressed by a subpopulation of colon can-
cer progenitor/stem cells. We identify direct PROX1
target genes and show that repression of a pro-
apoptotic member of the BCL2 family, BCL2L15, is
important for survival of PROX1+ cells under meta-
bolic stress. PROX1 inactivation after the establish-
ment of metastases prevented further growth of
lesions. Furthermore, autophagy inhibition efficiently
targeted metastatic PROX1+ cells, suggesting a po-
tential therapeutic approach. These data identify
PROX1 as a key regulator of the transcriptional net-
work contributing to metastases outgrowth in colo-
rectal cancer.
INTRODUCTION
Colorectal cancer (CRC) is one of the leading causes of cancer-
related mortality. The prognosis is especially poor for metastatic
CRC, with overall 5-year survival rates of 5%–8% (Cunningham
et al., 2010). Current treatment options include resection of sol-
itary metastases and combinations of anti-vascular endothelial
growth factor (VEGF) or epidermal growth factor receptor
(EGFR) inhibitors and cytotoxic therapy. However, these tar-
geted therapies are effective only in a small subset of patients
with metastatic disease and treatment benefits are short-lived,
further highlighting the need for a better understanding of meta-
static CRC (De Roock et al., 2011).
Wnt signaling is essential for the maintenance of normal
intestinal stem cells and is aberrantly activated in a significant
proportion of CRCs (Clevers, 2013). The evolutionary conserved
transcription factor PROX1 is a Wnt target gene in colon ade-
nomas, where it contributes to the transition from early to
dysplastic stage (Petrova et al., 2008). Prox1 is not expressed
in normal intestinal stem cells, demonstrating that only onco-
genic Wnt signaling triggers Prox1 expression (Petrova et al.,
2008). Increased epithelial-to-mesenchymal transition (EMT)
was recently reported in PROX1-expressing CRC cells in vitro
(Lu et al., 2012). However, the role of PROX1 in metastatic
CRC has not been investigated. Here, we report that PROX1 is
expressed in stem-like cells in a subset of Wnthigh colon car-
cinomas and metastases. PROX1 acts as a key regulator of
macrometastatic lesions outgrowth by promoting adaptation of
tumor cells to hypoxia and nutrient deprivation. Furthermore,
we show that targeting autophagy efficiently eliminates the
growth advantage of PROX1+ cells. We identify direct PROX1
target genes in CRC cells and show that a pro-apoptotic mem-
ber of BCL2 family, BCL2L15, is one of the downstream effectors
of PROX1. Our data thus identify a cancer-specific component of
the Wnt signaling required for outgrowth of metastases and sug-
gest that inhibition of PROX1, or PROX1-regulated pathways,
might constitute a new therapeutic approach.
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RESULTS
PROX1 Is Expressed in Progenitor/Stem Cells in Wnthigh
Colon Cancer Metastases
We examined whether PROX1 expression correlates with Wnt
signaling, stem-like/progenitor markers, cell differentiation, and
proliferation, using transcriptomes of 166 primary CRCs and
20 lung metastases (Sheffer et al., 2009). PROX1 expression
significantly correlated with stem/progenitor cell markers and
Wnt targets LGR5, ASCL2, RNF43, and EPHB2 (Clevers, 2013)
in primary tumors, and this correlation was further significantly
increased in lung metastases (Figure 1A; p < 0.05). In contrast,
PROX1 expression in metastases anticorrelated with the differ-
entiation marker KRT20 (Figure 1A). Analysis of the proliferation
signature MKI67, FOXM1, MYC, and AURKB (Jung et al., 2011)
revealed that PROX1 levels did not correlate with the signature
in primary tumors, whereas PROX1low metastases had a lower
proliferation index (Figure 1B).
We next asked how PROX1 expression correlates with mo-
lecular subtypes of CRC described by Budinska et al. (2013)
and Sadanandam et al. (2013). Highest PROX1 levels were
found in Wnthigh subtypes in both classification schemes (Fig-
ures S1A and S1B). In contrast, PROX1 was low in more-differ-
entiated subtypes, such as the subtype A with high expression
of differentiation markers and subtype C with high frequency of
cancer-specific DNA hypermethylation (CIMP-H) of the Budin-
ska et al. classification. Most of CIMP CRCs are also mismatch
repair (MMR) deficient due to hypermethylation of the MLH1
gene promoter (Truninger et al., 2005). In agreement with these
results, PROX1 was low in MMR-deficient CRCs (Figures S1C–
S1E). We further confirmed these data using the Pan-European
Trials in Alimentary Tract Cancers database, containing micro-
satellite instability status analysis for 688 CRC primary colon
carcinomas (Roth et al., 2010; Figure S1F).
The bioinformatics analysis predicted that PROX1 correlates
with stem/progenitor markers, high Wnt signaling, and prolifera-
tion and anticorrelates with differentiation markers. Interrogation
of transcriptomes from human CRC stem cells, stratified by the
levels of Wnt signaling (de Sousa E Melo et al., 2011), demon-
strated that PROX1 was significantly higher in Wnthigh versus
Wntlow cancer stem cells (Figure 1C; p = 9.73 104). To evaluate
PROX1 protein levels in metastasis versus primary tumor, we
stained 33 matched primary CRCs and their metastases. Lung
and lymph node metastases had significantly higher levels of
PROX1 in comparison to the primary tumors, with a positive
trend for other metastatic sites (Figures 1D, 1E, and S1G). To
establish whether PROX1 is expressed in stem/progenitor cells,
we analyzed coexpression of PROX1 and EPHB2, CD44 and
BMI1, previously shown to encompass progenitor/stem cell
populations (Todaro et al., 2014; Martorell et al., 2014; Merlos-
Sua´rez et al., 2011; Kreso et al., 2014). We also analyzed b-cat-
enin nuclear/cytoplasmic localization as a marker of Wnt
pathway activation, proliferation, and differentiation. In agree-
ment with the bioinformatics analyses, differentiated KRT20+
cells did not express PROX1 and, in metastases, cell prolifera-
tion correlated with levels of PROX1 (Figures 1F and S1H–
S1J). The majority of PROX1+ cells also coexpressed EPHB2
and BMI1, 50% had nuclear/cytoplasmic b-catenin, and 17%
coexpressed CD44 or proliferation markers. A significant pro-
portion of EPHB2+, BMI1+, CD44+, and PH3+ cells did not ex-
press PROX1 (Figures 1G–1I). Thus, in human metastases,
PROX1 partially colocalizes with markers of stem/progenitor
cells, proliferation, and activated WNT signaling.
To extend our observations to a model with a well-character-
ized stem cell compartment, we analyzed adenomas from
Apcfl/fl;Lgr5-EGFP-Ires-CreERT2mice. GFP marks Lgr5+ normal
and transformed stem cells, which give rise to differentiated
progeny in both normal intestine and adenoma (Schepers
et al., 2012). Fifty to sixty percent of GFPhigh, GFPlow, EphB2+,
or proliferating 5-ethynyl-20-deoxyuridine (EdU)+ cells expressed
Prox1, whereas Prox1 was absent in differentiated lysozyme+
Paneth cells or Krt20+ enterocytes (Figures 1J and S1K). In line
Figure 1. PROX1 Is Expressed in Stem-like Cells in Wnthigh CRC Metastases
(A) PROX1 expression in CRC metastases correlates with activated Wnt pathway and stem-like/progenitor signature, and it anticorrelates with differentiation
marker KRT20. Correlation analysis is based onGSE41258 (Sheffer et al., 2009). Data are presented as box andwhiskers; Spearman correlation coefficient: 1.53
interquartile range (IQR).
(B) PROX1 expression in CRC metastases correlates with proliferation. Samples from primary tumors and lung metastases (Sheffer et al., 2009) were divided in
three categories by PROX1-expression levels. The average expression of proliferation signature (black line) is plotted in log2 across the six categories. The gray
area represents the average expression of all genes.
(C)WNThigh CRC stem cells produce higher levels of PROX1. Expression analysis is based onGSE33112 (de Sousa EMelo et al., 2011). Data are presented as box
and whiskers; Log expression values: 1.5 3 IQR.
(D) PROX1 protein is increased in CRC metastases. Samples were scored as shown in Figure S1C. Student’s t test with FDR correction; *p < 0.05.
(E) Summary of PROX1 expression analyses in 33 primary tumors and metastases.
(F) PROX1 protein levels correlate with proliferation in CRC metastases. Percentages of PROX1+ and phosphohistone H3+ cells in primary tumors (n = 7) and
corresponding lung (n = 10) and liver (n = 6) metastases. Data are presented as mean ± SEM.
(G) PROX1 is expressed in a subset of progenitor/stem cells in CRC metastases. Staining for EPHB2, CD44, BMI1, b-catenin, and phosphohistone H3. Inserts: ex-
amplesof cytoplasmicandmembranous localizationofb-catenin.Whitearrows: cells coexpressingPROX1and the indicatedmarker. The scale bar represents50mm.
(H and I) Quantification of PROX1 expression data shown in (G). PROX1 expression in the indicated human tumor cell populations (H) or marker expression levels
in PROX1+ tumor cells (I). Data are presented as mean ± SEM.
(J) Prox1 is expressed in a subset of mouse transformed intestinal stem/progenitor cells. Staining for Prox1, GFP, EphB2, Krt20, or lysozyme in Apcfl/fl;Lgr5-
EGFP-CreERT2 adenomas or normal intestine. Proliferating cells were identified by EdU incorporation assay. The scale bar represents 20 mm.
(K) Prox1 depletion decreases clonogenic growth of AKP organoids. AKP cells were transduced with the control or PROX1 shRNAs, sorted to isolate single GFP+
cells, and plated in Matrigel. Colony number /well was determined at day 15. Student’s t test; ***p < 0.001. Data are presented as mean ± SEM.
(L) Prox1 mRNA levels in the control or shPROX1 transduced AKP organoids. Student’s t test; **p < 0.01. Data are presented as mean ± SEM.
(M and N) Stem/progenitor and Wnt target gene expression in AKP organoids following Prox1 depletion at days 5 and 14. Data are presented as mean ± SEM.
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Figure 2. PROX1 Controls CRC Metastasis
(A) PROX1 levels in DLD1-PROX1, DLD1-PROX1mut, or control cells and tumor lysates. Western blotting for the indicated proteins.
(B) PROX1 promotes growth of metastases. Luciferase-tagged DLD1 cells overexpressing wild-type PROX1 (PROX1), mutated PROX1 (PROX1Mut), or trans-
fected with control vector (control) were implanted intracecally in nonobese diabetic (NOD)-severe combined immunodeficiency (SCID); IL-2Rg/ mice and
detected by bioluminescent imaging. The scale bar represents 8 mm.
(C) Comparable size of primary tumors. n = 9/group. Data are presented as box and whiskers; Tukey appearance.
(D) PROX1 overexpression does not affect metastasis incidence. Tumor cells were identified by staining for KRT20. Data are presented as box and whiskers;
Tukey appearance.
(E–G) PROX1 promotes growth of individual metastases. One-way ANOVA; *p < 0.05; ***p < 0.001. Data are presented as box and whiskers; Tukey appearance.
(legend continued on next page)
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with previous results, normal intestinal stem cells were Prox1
(Petrova et al., 2008; Figures 1J and S1L). These data show
that, as in human tissues, a subset of transformed intestinal
stem cells produces high levels of Prox1. Furthermore, a propor-
tion of GFPlow/EphB2+/EdU+ adenoma progenitor cell popula-
tion, but not more-differentiated cells, maintain Prox1 expres-
sion. We conclude that (1) PROX1 expression partially overlaps
with other cancer stem cell (CSC)/progenitor markers, (2) many
proliferating cells in the tumors are PROX1-negative, (3) PROX1
is not expressed in differentiated cells, and (4) PROX1 expression
is increased in metastases in comparison to the primary tumors.
Thus, PROX1 is induced only upon transformation and it defines
a subset of cancer stem/progenitor cells, which themselves are
moderately proliferative but, when present in metastases, signify
high proliferative activity.
PROX1 Controls CSC Colony-Forming Ability
To study whether PROX1 contributes to the clonogenic
growth of CRC cells, we used intestinal organoids from Apcfl/fl;
KrasLsl-G12D; Tp53fl/fl;villin-CreERT2 (AKP) mice. In addition to
high Wnt signaling, such intestinal epithelial cells carry an onco-
genic mutation in Kras and loss of the tumor suppressor p53,
thus recapitulating major pathways important for development
of CRC (Fearon, 2011). Similar to human CRCs and Apcfl/fl;
Lgr5-EGFP-Ires-CreERT2 adenomas, we observed partially
overlapping localization of Prox1 and intestinal stem cell/pro-
genitor markers Lgr5, nuclear b-catenin, EphB2, and Cd44; pro-
liferation markers phosphohistone H3 and Ki67; and absence of
Prox1 expression in differentiated Krt20+ and Krt6+ cells (Figures
S1M and S1N). We next tested whether Prox1 is necessary to
sustain growth of AKP organoids in a colony-forming assay,
where a single stem cell gives rise to a 3D ‘‘organoid’’ structure
(Sato et al., 2011). Downregulation of Prox1 significantly
decreased the number of colonies formed by single AKP cells,
thus demonstrating that Prox1 maintains clonogenic growth
(Figures 1K and 1L). Expression of progenitor/stem cell markers
and Wnt target genes Lgr5, Ascl2, Rnf43, and EphB2 was not
modified in early organoids at day 5, despite downregulation of
Prox1 (Figure 1M). However, their expression was lower in orga-
noids by day 15 (Figure 1N). Taken together with our previous
data showing that Prox1 does not affect general Wnt reporter ac-
tivity (Petrova et al., 2008), these results indicate that Prox1 does
not directly regulate stem/progenitor gene expression or general
Wnt signaling, but it rather maintains the clonogenic capacity of
CSCs.
PROX1 Controls CRC Metastasis
Analyses of human tumor samples indicated that PROX1
expression is elevated in a subset of metastases (Figure 1E),
consistent with potential involvement of PROX1 in metastatic
CRC. To clarify this, we used an orthotopic model, in which
CRC cells formmetastases in lymph nodes, liver, and lungs after
intracecal injection (Ce´spedes et al., 2007). To study if PROX1 is
sufficient to promote metastasis, we overexpressed PROX1 and
its inactive form PROX1mut, bearing mutations in the DNA-bind-
ing domain, in PROX1-negative DLD1 CRC cells. As another
control, we used cells transfected with an empty vector (Fig-
ure 2A). The primary tumor size was similar between the groups,
and there was no difference in primary tumor weights (Figures 2B
and 2C). However, significantly more DLD1-PROX1 cells were
present in lungs, liver, and lymph nodes (Figure 2B). Metastatic
incidence was increased only in lymph nodes of PROX1 group
(Figure 2D). In all tissues, PROX1+ metastases were 2- to
5-fold larger than the control lesions (Figures 2E–2G). PROX1+
metastases displayed higher levels of proliferation marker phos-
phohistone H3. Strikingly, proliferating cells were observed
throughout the lesion in DLD1-PROX1 metastases, whereas in
the control, metastases proliferation was restricted to the outer
rim as a result of massive central necrosis (Figure 2H).
We next asked whether PROX1 depletion in PROX1+ SW620
cells affects development of metastases (Figures S2A–S2C).
Depletion of PROX1 did not affect growth of primary tumors;
however, we observed marked differences in the development
of metastases (Figures S2D–S2F). In this case, there were
more PROX1+ metastases, which were also bigger in compari-
son to the controls (Figures S2E and S2F). Depletion of PROX1
reduced metastases proliferation and induced extensive necro-
sis and apoptosis, whereas little cell death was observed in pri-
mary tumors (Figures S2G and S2H).
To confirm that these phenotypes were not the result of long-
term cell selection, we studied SW480R/PROX1si cells, in which
PROX1 is suppressed upon administration of doxycycline (Pet-
rova et al., 2008; Figure S2I). Depletion of PROX1 reduced me-
tastases size and incidence without affecting the primary tumor
(Figures S2J and S2K). Doxycycline treatment had no effect on
SW480R/GFPsi metastases, in which a control small hairpin
RNA (shRNA) was induced (Figures S2J and S2L). Similar to
other models, suppression of PROX1 resulted in formation of
large central necrotic areas (Figure S2M). In summary, loss-
and gain-of-function experiments show that PROX1 is necessary
and sufficient to promote CRC metastases.
PROX1 Fuels Metastases Outgrowth
Metastasis requires several steps: invasion, extravasation, sur-
vival in the circulation, colonization of distal organs, and
outgrowth of macrometastases (Chaffer and Weinberg, 2011).
PROX1 promoted EMT in vitro by suppressing E-cadherin (Lu
et al., 2012). However, in our hands, PROX1 and PROX1+ cells
expressed comparable levels of E-cadherin and EMT marker vi-
mentin (Figures 3A and S3A). PROX1 did not increase invasion in
in vitro assays or local invasion in primary tumors, and vascular
density was comparable in PROX1+ versus PROX1 tumors (Fig-
ures S3B–S3E). Thus, enhanced local invasion and angiogenesis
are not major contributing factors in our models.
To test the role of PROX1 during the subsequent steps of
metastasis, we injected enhanced GFP (EGFP)-tagged SW620
(H) Only wild-type PROX1 promotes growth of metastases. Upper row: increased size of DLD1-PROX1 lung metastases. Middle row: decreased cell death in
DLD1-PROX1 metastases. Arrows, necrotic areas. Lower row: increased proliferation in DLD1-PROX1 metastases. Chromogenic staining for KRT20 (brown) or
fluorescent staining for phosphohistone H3 (red), KRT20 (green), and DNA (blue). The scale bars represent 200 mm (upper and middle panels) and 100 mm (lower
panel).
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Figure 3. PROX1 Promotes Metastatic Outgrowth
(A) Lungmicrometastases 3 days after the tail vein injection of SW620-shCtr or SW620-shPROX1 cells. Staining for PROX1 (red), vimentin (green), and DNA (blue).
The scale bar represents 20 mm.
(B) PROX1 is dispensable for tumor cell extravasation. Number of lung metastatic foci after injection of SW620-shCtr or SW620-shPROX1cells into the tail vein of
NOD-SCID; IL-2Rg/ mice. Tumor cells were stained for human vimentin. Data are presented as mean ± SEM.
(C) PROX1 promotes growth of metastases. Average size was calculated by dividing total metastases area by number of metastases and normalized to tissue
area analyzed. Two-way ANOVA; *p < 0.05; ***p < 0.001. Data are presented as mean ± SEM.
(D) PROX1 depletion prolongs survival. Kaplan-Meyer survival curve of mice injected with SW620-shCtr or SW620-shPROX1 cells. Log rank (Mantel-Cox) test;
***p < 0.001.
(E) PROX1 depletion prevents growth of macrometastases. Ex vivo analysis of SW620-shCtr and SW620shPROX1 EGFP+ cells 7 weeks after tail vein injection
into NOD-SCID; IL-2Rg/ mice. The scale bars represent 750 mm (lung), 1 mm (liver), and 2.5 mm (lymph node and dorsal muscle).
(legend continued on next page)
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PROX1+ and PROX1 cells into the tail vein. PROX1+ or PROX1
CRC cells formed similar number of lung colonies at days 2, 5,
and 7 post-injection (Figures 3A and 3B). Thus, PROX1 is
dispensable for tumor cell survival in the blood stream or in early
metastases. However, PROX1 depletion prevented further met-
astatic outgrowth and increased animal survival (Figures 3C and
3D). PROX1 cells were unable to establish colonies in most or-
gans, with a notable exception of skeletal muscle (Figures 3E
and 3F). Similar to orthotopic models, proliferation and apo-
ptosis were increased and decreased, respectively, in PROX1+
metastases compared to PROX1 lesions, as determined by
phosphohistone H3 staining and TUNEL assay (Figures 3G and
3H). Overall, these results indicate that PROX1 mainly promotes
outgrowth of tumor cells in target organs.
PROX1 Promotes Resistance to Hypoxia and
Nutrient Deprivation
To investigate the underlying mechanism of PROX1-mediated
metastatic outgrowth, we analyzed cell growth under standard
cell culture conditions. Modulation of PROX1 levels in three hu-
man CRC lines did not affect cell growth in 2D (Figures 4A and
S4A). We next studied the ability of these cells to form tumor
spheroids. In agreement with AKP organoid results, in all three
lines, PROX1+ spheroid size and number were increased in
comparison to PROX1-negative spheroids (Figures 4B–4E and
S4B–S4D). Consistent with in vivo models, PROX1+ spheroids
proliferated more and underwent apoptosis less than PROX1
spheroids (Figures 4F–4I and S4D).
In tumor spheroids, diffusion of nutrients and oxygen is
decreased in the center, resulting in a hypoxic/low-nutrient envi-
ronment and cell death (Hirschhaeuser et al., 2010). Whereas the
central part of PROX1 spheroids was filled with dead cells,
PROX1+ spheroids cores contained live cells and more cells
proliferated at a distance from the surface (Figure 4J), suggest-
ing that PROX1 promotes cell survival and proliferation in hypox-
ia and nutrient-poor environments. To directly test this, we
cultured DLD1-PROX1 and DLD1 control cells in 0.1% O2 and/
or under reduced glucose or glutamine conditions. Hypoxia
induced stabilization of HIF1a in both PROX1 and PROX1+
DLD1 cells (Figures 5A and 5B). However, by 72 hr, DLD1 control
cells became growth arrested and apoptotic, as determined by
staining for activated caspase-3 (Figures 5C–5F). In contrast,
hypoxic DLD1-PROX1 cells had somewhat enhanced prolifera-
tion and low cell death (Figures 5D, 5F, and 5G). PROX1+ cells
were also more resistant to cell growth arrest and cell death eli-
cited by the low glucose or glutamine, but not by etoposide,
which induces apoptosis through DNA damage (Figures 5D,
5F, 5G, and S5A). Similar results were observed in another cell
line SW620 (Figures S5A–S5D). These data indicate that
PROX1 sustains cell survival and proliferation under metabolic
stress.
PROX1 Promotes Metabolic Adaptation
Increased glycolysis is one of the key characteristics of cancer
cells. However, cancer cells can also use oxidative phosphoryla-
tion rather than glycolysis to sustain growth (e.g., Haq et al.,
2013; Janiszewska et al., 2012). To better understand the mech-
anisms of increased fitness of PROX1+ CRC cells, we studied
their metabolic responses upon nutrients or oxygen deprivation.
Extracellular acidification rate (ECAR), a measure of glycolysis,
and cellular oxygen consumption rate (OCR), a measure of
oxidative phosphorylation, were comparable between DLD1-
PROX1+ and PROX1 cells under basal cell culture conditions
(Figures 5H and 5I). As expected, glucose deprivation decreased
glycolysis in both cells types (Figure 5H). PROX1 cells dis-
played little compensatory increase in OCR, indicative of their
inability to switch to an alternative fuel source. In contrast,
OCR was high in PROX1+ cells upon glucose deprivation, which
also paralleled increased survival of PROX1+ cells (Figures 5I
and 5G). In the absence of glutamine, PROX1+ cells, unlike the
control cells, sustained both OCR and ECAR and increased
glycolysis after treatment with the mitochondrial oxidative phos-
phorylation inhibitor trifluorocarbonylcyanide phenylhydrazone
(Figures S5E and S5F). Better adaptation to glucose or glutamine
starvation and oxidative phosphorylation inhibition was also
observed in PROX1+ SW620 cells (data not shown).
In order to evaluate cell metabolism in hypoxia, we measured
ECAR and OCR in cells cultured for 24 hr in 0.1% O2. SW620
PROX1+ cells had higher basal level of oxidative phosphorylation
in normoxia and also displayed a higher glycolysis rate in
response to hypoxia (Figures S5G and S5H). Similarly, DLD1-
PROX1 cells cultured in hypoxia and low glutamine displayed
higher levels of glycolysis in comparison to the control cells
(data not shown). Taken together, these data indicate that,
whereas not favoring either oxidative phosphorylation or glycol-
ysis, PROX1 promotes cell adaption to changes in fuel source.
Such metabolic fitness of PROX1+ cells would confer growth
advantages under unfavorable conditions that tumor cells en-
counter during metastasis outgrowth.
Continuous PROX1 Expression Is Necessary for
Growth CRC Metastases
To evaluate the therapeutic potential of targeting PROX1, we
studied whether ablation of PROX1 affects established metasta-
ses. SW480R/PROX1si cells, expressing a PROX1-targeting
shRNA under the control of doxycycline, were injected intra-
cecally. Doxycycline treatment was initiated 30 days later,
when both primary and metastatic lesions already developed.
PROX1 depletion did not affect primary tumors, despite downre-
gulation of PROX1 protein (Figures 6A, 6B, and S6A). However,
further growth of metastases was arrested in the absence of
PROX1, whereas they continued to grow in the control mice (Fig-
ures 6A, 6C, S6B, and S6C). Thus, PROX1 inhibition may be a
(F) Quantification of macrometastases size. Student’s t test; *p < 0.05; ***p < 0.001. Data are presented as box and whiskers; Tukey appearance.
(G) Increased proliferation (upper row) and decreased necrosis (lower row) in SW620shCtr liver metastasis. Staining for human vimentin (red), phosphohistone H3
(green), and DNA (blue) or chromogenic TUNEL assay (brown). The scale bars represent 50 mm (upper) and 100 mm (lower).
(H) Quantification of cell proliferation or apoptosis in metastases. Proliferating cells were determined by staining for phosphohistone H3 and apoptosis by TUNEL
assay. Two-way ANOVA; **p < 0.01; ***p < 0.001. Data are presented as mean ± SEM.
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Figure 4. PROX1 Promotes Cell Growth and Survival in 3D
(A) PROX1 does not affect cell growth in 2D conditions. Growth curves of DLD1 PROX1 control or PROX1Mut and SW620 shCtr or shPROX1 cells. Two-way
ANOVA; not significant (ns). Data are presented as mean ± SEM.
(B) PROX1 promotes growth of tumor spheroids. Cells seeded in qGel were cultured in complete culturemedium and spheroid size determined by phase-contrast
microscopy. Threshold >500 mm2 was used. Two-way ANOVA; ***p < 0.001. Data are presented as mean ± SEM.
(C) Macroscopic view of tumor spheroids. Cells were stained for F-actin (green) 21 days after seeding. The scale bar represents 2.5 mm.
(D) Microscopic appearance of PROX1, control, or PROX1Mut spheroids at day 15. The scale bar represents 200 mm.
(E) Quantification of spheroids number at day 21. Data are presented as mean ± SEM.
(F) PROX1 promotes proliferation of spheroids. Whole-mount staining for phosphohistone H3 (red), F-actin (green), PROX1 (light blue), and DNA (dark blue). The
scale bar represents 100 mm.
(legend continued on next page)
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useful therapeutic option for treatment of PROX1+ CRC
metastases.
Pharmacological Inhibition of Autophagy Targets
Metastatic PROX1+ Cells
With few exceptions, therapeutic targeting of transcription fac-
tors is difficult (Koehler, 2010). Therefore, we sought to identify
pharmacological approaches for targeting PROX1+ CRC cells.
One of the pathways that mediate stress-induced metabolic
adaptation is autophagy, a process of recycling cell components
to maintain nutrient flux and energy homeostasis (White, 2012).
To test whether autophagy underlies PROX1-induced survival
under metabolic stress, we treated cells with chloroquine (CQ),
which inhibits autophagy by preventing endosomal acidification.
CQ-treated PROX1+ and PROX1 cells accumulated enlarged
LC3B+ autophagosomes in hypoxia, demonstrating efficient
autophagy inhibition (Figure S6D). CQ prevented proliferation
of hypoxic PROX1+ cells, whereas it had little effect on
PROX1+ or PROX1 cells under normoxic conditions (Figures
6D, 6E, and S5E). We also treated cells with another autophagy
inhibitor, 3-methyl adenine (3-MA) (White, 2012). Similar to the
CQ, 3-MA induced cell death of PROX1+ cells under hypoxic
conditions (Figure S6F). Thus, autophagy inhibition and meta-
bolic stress induce a synthetically lethal phenotype in PROX1+
cells. It also suggests that autophagy inhibition, which is now un-
der clinical trials in metastatic CRC (http://clinicaltrials.gov/
show/NCT01006369), may preferentially target PROX1+ tumor
cells.
To evaluate this hypothesis, we injected mice intravenously
with PROX1+ or PROX1 SW620 cells and monitored the effects
of CQ on liver metastases. CQ was administered either at high
(40 mg/kg; Sasaki et al., 2012) or at low (10 mg/kg) dosage,
which better mimics the situation in patients (Kimura et al.,
2013). The high-CQ regimen significantly reduced the size, but
not the number, of liver metastases (Figures S6G and S6H).
Strikingly, these macrometastases had increased necrosis,
with frequently only a rim of live cells (Figures S6I and S6J).
PROX1 cells did not form liver macrometastases at this time
point, and CQ had no further effect on cell death (Figures S6G–
S6I). Importantly, although low-CQ regimen did not reduce liver
macrometastasis incidence or size (Figures 6F and S6K), it still
strongly induced tumor necrosis and decreased cell proliferation
(Figures 6G, 6H, S6L, and S6M).
Decreased angiogenesis can also lead to tumor necrosis.
Therefore, we quantified tumor vessel density. Vascular density
was comparable in treated versus control metastases (Figures
6H and S6N), arguing that CQ acts directly on tumor cells. Prolif-
erating cells in CQ-treated tumors were found only at the tumor-
stroma interface, characterized by abundant vasculature,
showing that treated cells need oxygen- and nutrient-replete
conditions to proliferate (Figures 6H, S6L, and S6N).
Intriguingly, PROX1 had little effect on orthotopically im-
planted primary tumors, whereas it promoted growth of metas-
tases (Figures 2, 6A–6C, and S2). To explain this differential
response, we analyzed proliferation and apoptosis in metasta-
ses versus primary tumors. In two different models, PROX1+
and PROX1 primary tumors proliferated at low and comparable
rates and had low levels apoptosis (Figures 6I, 6J, and S6O; data
not shown). In contrast, proliferation was high in PROX1+ metas-
tases, whereas apoptosis was induced in PROX1 metastases
(Figures 6J and S6O). Because only PROX1+ cells can produc-
tively use autophagy (Figure 6D), we compared responses to
autophagy inhibition of primary tumors and metastases. Treat-
ment with CQ did not affect primary tumor proliferation (Figures
6K, 6L, and S6P) or metastasis incidence (Figure S6Q). However,
CQ significantly suppressed proliferation of PROX1+metastases
(Figures 6K and 6L). Furthermore, although CQ treatment did
induce some necrosis in primary tumors, necrosis levels were
significantly higher in PROX1+ metastases (Figure 6M). Im-
portantly, the treatment had no effect on vascular density
(Figure S6R).
To better understand why PROX1+metastases respond better
than primary tumors to autophagy inhibition, we next compared
autophagy in primary versus metastatic lesions by quantifying
differences in LC3B levels between the control and CQ-treated
lesions. Such autophagic flux is a more accurate measure of
autophagy than the steady-state level of processed LC3B (Miz-
ushima et al., 2010). Autophagic flux was higher in metastases,
regardless of the levels of PROX1 (Figures 6N–6Q). Our data
thus show that CQ efficiently targets PROX1+ cells in macrome-
tastases. They also indicate that the metastatic CRC cells have
higher levels of autophagy, which points to increased metabolic
stress in the sites of metastases. Although the mechanisms
remain to be elucidated, these results show that PROX1+ metas-
tases may respond to autophagy inhibition in patients.
BCL2L15 Is aDirect Target of PROX1,which Suppresses
Tumor Growth
To study the transcriptional network regulated by PROX1, we
carried out chromatin immunoprecipitation sequencing (ChIP-
seq) and transcriptome analysis after small interfering RNA
(siRNA)-mediated knockdown of PROX1 in SW480R cells (Fig-
ure S7A). The analyses identified 23,450 PROX1-binding sites
(false discovery rate [FDR] < 0.001) and 444 PROX1-dependent
genes (FDR < 0.05 and fold change [FC] > 1.5). To find how
PROX1 DNA binding correlates with changes in gene expres-
sion, we mapped these genes to nearby ChIP-seq-binding re-
gions. Unaffected genes (mean expression value >8 and FC <
1.5) were used as reference. We observed that PROX1 preferen-
tially binds in the vicinity of genes induced by PROX1 depletion
(Figure S7B). Thus, as found in other cell types (e.g., Steffensen
et al., 2004), PROX1 acts as a transcriptional repressor.
(G) Quantification of proliferation in tumor spheroids. Data are presented as box and whiskers; Tukey appearance.
(H) Decreased apoptosis in PROX1-expressing spheroids. Staining for TUNEL assay (brown) and DNA (light blue). The scale bar represents 100 mm.
(I) Quantification of apoptosis, shown as percentage TUNEL+ cells in sections. DLD1, one-way ANOVA; ***p < 0.001. SW620, Student’s t test; ***p < 0.001. *p <
0.05; **p < 0.01. Data are presented as box and whiskers; Tukey appearance.
(J) Necrotic core is present in control but PROX1-expressing spheroids. Staining for PH3 (red) and DNA (blue). White arrowheads, necrotic areas. The scale bar
represents 50 mm.
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Figure 5. PROX1 Promotes Metabolic Adaptation In Vitro
(A) HIF1a is stabilized by hypoxia both in DLD1-PROX1 or control cells. Staining for HIF1a (green) and DNA (blue). The scale bar represents 50 mm.
(B) HIF1a levels in PROX1+ or PROX1 cells after 12 hr in hypoxia. Western blotting for the indicated proteins.
(C) PROX1+ cells proliferate in hypoxia. Cells were cultured in normoxia or 0.1% O2 for 72 hr. Staining for PH3 (red) and DNA (blue). The scale bar represents
50 mm.
(D) PROX1+ cells proliferate under metabolic stress. Cells were cultured in the indicated conditions for 72 hr and stained for phosphohistone H3 and DNA. Data
are presented as mean ± SEM.
(E) PROX1 reduces cell apoptosis under metabolic stress conditions. Staining for cleaved caspase-3 (green) and DNA (blue) after 72 hr. The scale bar represents
200 mm.
(F) Quantification of apoptosis for data shown in (E). One-way ANOVA; **p < 0.01; ***p < 0.001. Black *, PROX1 versus control. Two-way ANOVA; *p < 0.05; ***p <
0.001. Red *, treatment versus complete medium in normoxia. Data are presented as mean ± SEM.
(G) Quantification of DLD1 cell number after 3 days incubation in the indicated conditions. *p < 0.05; ***p < 0.001. Cell number was determined by CyQuant assay.
Data are presented as mean ± SEM.
(H) Glucose deprivation decreases lactate production in both DLD1-PROX1 and control cells. ECAR was measured in cells cultured at two different densities.
Data are presented as mean ± SEM.
(I) PROX1+, but not control, cells increase oxidative phosphorylation in the absence of glucose. OCR was measured in the same samples as for (H). Data are
presented asmean ±SEM. Two-way ANOVA; *p < 0.05; **p < 0.005; ***p < 0.001; red *, PROX1 versus control in indicated condition; black *, significant change of
the same cell type in different conditions.
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As PROX1 promoted survival of both DLD1 and SW480R cells,
we reasoned that important direct targets should be repressed in
both cell lines. To identify such targets, we combined ChIP-seq
data with gene expression profiling results in two cell types. We
identified 40 genes, repressed by PROX1 and carrying PROX1-
binding sites (FDR < 0.05; Tables S1, S2, and S3), out of which
seven genes (ABAT, BCL2L15, CAV1, IQGAP2, SEMA3C,
SLC7A7, and TNFRSF9) were repressed by PROX1 more than
2-fold (Figures 7A, S7C, and S7D). For most of these genes,
the direct connection to CRC progression remains to be investi-
gated. However, BCL2 family member, BCL2L15, acts as a con-
ditional pro-apoptotic gene in CRC cells in vitro (Dempsey et al.,
2005) and Cav1/ mice have more aggressive lesions in a ge-
netic model of intestinal cancer (Friedrich et al., 2013).
We tested next whether metabolic stress conditions affected
the expression of BCL2L15 and CAV1. Hypoxia induced expres-
sion of BCL2L15 and CAV1 in PROX1, but not PROX1+ cells,
suggesting that they act as PROX1 effectors in cells under meta-
bolic stress (Figures 7B and 7C). At the same time, PROX1+ and
PROX1 cell response to hypoxia was comparable, as judged by
expression levels of the HIF1a target VEGF-A (Figure 7D). We
overexpressed BCL2L15, CAV1, or another PROX1 target
TNFRSF9 in PROX1+ CRC cells (Figure S7E) and tested growth
and survival of these cells under normoxia and hypoxia.
BCL2L15 and, to a lesser extent, CAV1 reduced proliferation
and increased apoptosis of PROX1+ cells under hypoxia (Figures
7E, 7F, and S7F). In contrast, overexpression of TNFRSF9 had
no effect (Figure S7F). Furthermore, BCL2L15 overexpression
in PROX1+ CRC cells drastically reduced the number and size
of metastases after intravenous (i.v.) injections (Figures 7G–7J).
To test the effects of BCL2L15 inactivation, we used the AKP
intestinal organoid model, in which Bcl2l15 is expressed in
Prox1-negative cells and is further induced after Prox1 depletion
(Figures S7G and S7H). We found that Bcl2l15 depletion
enhanced clonogenic growth of intestinal organoids in vitro (Fig-
ures 7K and S7I), as well as proliferation and growth of organoid-
derived tumors in vivo (Figures 7L–7N and S7J), without affecting
cell survival (Figure 7O). As expected, Prox1 depletion reduced
colony formation and tumor growth under the same conditions
(Figures 7K–7O, S7I, and S7J).
To further analyze the significance of BCL2L15 and CAV1
regulation by PROX1 in human CRC in vivo, we studied
BCL2L15 and CAV1 protein localization in human CRC.
BCL2L15 and PROX1 displayed amutually exclusive localization
pattern both in metastases and primary tumors (Figures 7P and
S7K; data not shown). In contrast, CAV1 was generally low in
CRC cells independently of PROX1 status (data not shown).
These results suggest that BCL2L15 suppression is a more-spe-
cificmarker for PROX1 activity. Moreover, luciferase reporter as-
says showed that PROX1 directly repressed the activity of the 30
PROX1-binding region in the BCL2L15 locus (Figures S7L and
S7M). BCL2L15 mRNA levels were also strongly reduced in
CRC tumors (n = 230; p = 2.11 3 108; Figure 7Q) and showed
a significant negative correlation with PROX1 (Figure 7Q; p = 1.8
3 104). In summary, our genome-wide analyses identified a
number of potential direct PROX1 targets in CRC (Table S1),
whose roles still need to be investigated. Here, we show that
BCL2L15 is an important, even if likely not the only, effector of
PROX1 in CRC, whose suppression in part recapitulates the
effects of PROX1.
DISCUSSION
We report that the colon-cancer-specific Wnt target PROX1 is
highly expressed in colon cancer metastases, where it is present
in a subset of cancer stem/progenitor cells. We also show that, in
advanced CRC, PROX1 sustains growth of macrometastases
through the evasion of apoptosis andmetabolic adaptation. Pre-
vious studies investigated the mechanisms of local invasion in
primary CRC tumors. They established important roles for Wnt
and Notch signaling, EMT, and the tumor-stroma interactions
(e.g., Dolznig et al., 2011; Sonoshita et al., 2011; Spaderna
et al., 2008; Wolf et al., 2012). However, mechanisms governing
outgrowth ofmetastases are not well understood. Yetmetastatic
CRC is a major clinical challenge, with limited patient survival
and few therapeutic options available, especially for patients
with activating KRAS mutations, which confer resistance to
anti-EGFR therapy (Cunningham et al., 2010; Van Emburgh
et al., 2014).
In this study, we investigated the role of the transcription factor
PROX1 in the development of CRC metastases. Expression of
PROX1 in primary CRC tumors is not an independent prognostic
factor (Skog et al., 2011). However, we found that PROX1 levels
are generally increased in metastases and a proportion of
PROX1 primary tumors give rise to PROX1+ metastases. Large
expression data sets from metastatic lesions will clarify whether
high levels of expression of PROX1 in a metastasis correlates
with survival after relapse. Nevertheless, already now our data
suggest that, in advanced CRC, PROX1 may be important in
the context of metastatic disease.
Analysis of PROX1 expression patterns in human metastases
and mouse models demonstrated that PROX1 is expressed only
upon transformation and it may delineate a distinct subpopula-
tion of cancer stem/progenitor cells. Furthermore, in vitro ana-
lyses of the intestinal organoid model demonstrated that, while
Prox1 does not directly control the expression of stem/progeni-
tor-associated genes or general Wnt pathway activity, it is
essential to maintain clonogenic growth. Our data are in agree-
ment with the results of Wiener et al., who show that Prox1 is
essential for the expansion of the stem cell pool in transformed
but not in normal intestinal stem cells (Wiener et al., 2014).
Through the analysis of mouse models of CRC metastasis, we
found that PROX1 is dispensable for growth of primary tumors,
cell survival in the bloodstream, or extravasation; however, it
promotes outgrowth of metastases. At least in part, this property
of PROX1 relies on its ability to override cell death imposed by
metabolic stress, such as hypoxia or low-nutrient environment.
Taken together, our data suggest that, in CRCmetastases, there
exists a subpopulation of PROX1+ stem/progenitor cells, which
are highly resistant to metabolic insults and can thus fuel meta-
static growth. These data identify PROX1 as an important player
in CRC stem/progenitor cells maintenance and function.
To investigate the mechanisms of PROX1 action in CRC, we
carried out PROX1 genome location analysis and identified
genes regulated by PROX1. As expected, a significant number
of direct PROX1 target genes were identified (Table S1), and
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we began investigating their individual contribution. Here, we
show that a pro-apoptotic member of the BCL2 family,
BCL2L15 (Dempsey et al., 2005), is induced in hypoxic PROX1,
but not PROX1+, cancer cells and that BCL2L15 can in part reca-
pitulate the phenotype of PROX1 deficiency, such as increased
clonogenic growth of tumor organoids or tumor development
in vivo. These results indicate that apoptosis evasion under
metabolic stress conditions is important for the prosurvival func-
tion of PROX1+ in metastases. Most likely, the role of other
potentially interesting targets and their combinatorial interac-
tions will need to be addressed in the future. Of interest, Annexin
A1, identified as a PROX1 effector by Wiener et al. (2014) is
another direct target of PROX1 in our data set (Table S1).
With few exceptions, transcription factors are considered
undruggable. To overcome this limitation, we searched for
pharmacological approaches to target PROX1+ tumor cells.
We found that inhibition of autophagy, a catabolic process
providing an alternative energy source, eliminates the growth
advantage of PROX1+ CRC cells and decreases metastatic
burden. Of interest, following CQ treatment, viable tumor cells
are located in the vicinity of blood vessels and they remain
accessible for cytotoxic drugs. Thus, a combination of targeted
anti-PROX1 therapy with antiproliferative/cytotoxic 5-fluoro-
uracil-based chemotherapy might be pursued as a potential
treatment option for CRC patients with PROX1+ metastatic
disease.
We propose the following working model of PROX1’s role in
metastasis: high Wnt signaling induces PROX1 expression in
CRC cells and PROX1+ cancer stem/progenitor cells become
resistant to metabolic stress, in part through the repression of
BCL2L15. Because PROX1 is produced only in CRC, but not
normal stem cells, and metabolic stress is high in metastases,
these data provide one of the mechanisms of how oncogenic
Wnt signaling induces cancer cell adaptation and promotesmet-
astatic cell outgrowth.
A related intriguing question is whether increased fitness of
PROX1+ tumor cells reflects the role of PROX1 in normal tissues.
The highest levels of Prox1 are found in lens fiber cells (Oliver
et al., 1993). The lens is an avascular organ, located in a physio-
logically hypoxic and glucose-poor environment (Mathias et al.,
1997; Trayhurn and Van Heyningen, 1972), and it is not fully un-
derstood how the lens maintains homeostasis in such condi-
tions. Similarly, PROX1+ lymphatic vessels, unlike blood vessels,
do not need basementmembrane or pericytes to survive, grow in
relatively hypoxic environment, and do not regress after removal
of proliferative stimuli (Baluk et al., 2005). Thus, it seems plau-
sible that PROX1 enhances adaptation of normal cells to unfa-
vorable metabolic conditions.
An important observation of this study is the differential role
of PROX1 in metastases versus primary tumors in advanced
colorectal cancer. In our models, all of which carry mutations
in oncogenic and tumor suppressor genes APC, KRAS, and
TP53, PROX1 suppression decreasedmetastasis size and prolif-
eration, whereas having little effect on the size or proliferation of
primary tumors. Whereas the mechanisms are yet unknown, we
propose that PROX1 is needed to provide a survival advantage
to metabolically stressed cells. This is supported by the fact
that CQ treatment is more effective in reducing growth of
Figure 6. Therapeutic Potential of Targeting PROX1
(A) PROX1 depletion in established metastases prevents further growth. SW480R/PROX1si cells, implanted intracecally into NOD-SCID; IL-2Rg/ mice, were
detected by in vivo bioluminescence imaging. Insert: macroscopic liver metastases in control SW480R/PROX1si mouse. The scale bar represents 750 mm. Two-
way ANOVA; ***p < 0.001. Data are presented as mean ± SEM.
(B) PROX1 suppression does not affect weight of primary tumors. Data are presented as box and whiskers; Tukey appearance.
(C) PROX1 suppression prevents further growth of metastases. ***p < 0.001. Data are presented as box and whiskers; Tukey appearance.
(D) Inhibition of autophagy prevents PROX1-dependent adaptation to hypoxia. CQ, chloroquine. SW620 shCtr or shPROX1 cells were cultured for 72 hr in
normoxic or hypoxic conditions in the presence or absence of 5 mM CQ. Staining for phosphohistone H3 (red), GLUT1 (green), and DNA (blue). The scale bar
represents 50 mm.
(E) Quantification of cell proliferation. *p < 0.05; ***p < 0.001. Data are presented as mean ± SEM.
(F) Low-dose CQ does not affect metastases size. Quantification of metastases area in mice injected i.v. with tumor cells and treated with 10 mg/g CQ or PBS
from day 7 post-implantation. Both necrotic and live tumor areas of metastases >100 mm2 were quantified. Data are presented as box and whiskers; Tukey
appearance.
(G) CQ treatment induces necrosis in metastases. Quantification of necrotic areas in liver metastases in mice treated with 10 mg/g CQ or PBS. Necrosis was
evaluated at tumor-stromal interface, metastasis center, and in the entire lesion. **p < 0.01; ***p < 0.001. Data are presented as mean ± SEM.
(H) Low-dose CQ does not affect blood-vessel density. Left column: staining for endothelial marker endomucin (green), phosphohistone H3 (light blue), and DNA
(blue). Yellow scattered line: highly vascularizedmetastatic area close to the liver stroma.White scattered line: the necrotic area. The scale bar represents 200 mm.
Right column: staining for PROX1 (red), blood vessel marker endomucin (green), and DNA (blue). The scale bar represents 100 mm.
(I) CQ treatment reduces proliferation of PROX1+ metastases but has little effect on primary tumors. Staining for PH3 (light blue), PROX1 (red), and DNA (blue).
White scattered lines, tumor area; white asterisk, areas of necrosis; yellow arrows, PH3+ cells. The scale bar represents 100 mm.
(J) Quantification of proliferation in orthotopic SW620 shCtr or shPROX1 primary tumors or metastases. Two-way ANOVA; ***p < 0.001. Data are presented as
mean ± SEM.
(K) CQ treatment reduces proliferation of PROX1+ metastases. Staining for EdU (red), PROX1 (light blue), pimonidazole (green), and DNA (blue) of orthotopic
SW620 shCtr or shPROX1 primary tumors or metastases following treatment with PBS or CQ. The scale bar represents 200 mm.
(L) Quantification of proliferation as determined by EdU incorporation. Data are presented as mean ± SEM.
(M) CQ treatment induces necrosis in PROX1+ metastases. Data are presented as mean ± SEM.
(N) Higher autophagic flux in metastases as compared to primary tumors. Staining for LC3B (red) and DNA (blue). Hypoxic areas are identified by staining for
pimonidazole (green). The scale bar represents 25 mm.
(O) Quantification of LC3B+ cancer cells in primary tumors and metastases. Data are presented as mean ± SEM.
(P) Quantification of LC3B+ foci in individual cells. Two-way ANOVA; *p < 0.05; **p < 0.01. Data are presented as mean ± SEM.
(Q) Examples of images used for quantification in (O) and (P). Staining for LC3B (red) and DNA (blue). The scale bar represents 2 mm.
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Figure 7. BCL2L15 Is a Direct PROX1 Effector Gene
(A) Heatmaps of selected PROX1 targets in two cells lines.
(B–D) BCL2L15 andCAV1 are induced in hypoxia in the absence of PROX1. Quantitative PCR analysis of the indicated transcripts. Cells were cultured in normoxia
or hypoxia for 24 hr. Data are presented as mean ± SEM.
(E and F) BCL2L15 and CAV1 suppress cell proliferation and induce apoptosis in hypoxia. Cells were cultured for 72 hr in normoxia or 0.1% O2. Proliferating or
apoptotic cells were identified by staining for phosphohistone H3 or activated caspase-3. Two-way ANOVA; *p < 0.05; **p < 0.01; ***p < 0.001. Data are presented
as mean ± SEM.
(legend continued on next page)
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PROX1+ metastasis versus primary tumors and that metastases
have higher levels of autophagy. Interestingly, whereas generally
PROX1 increases metastases size, PROX1+ and PROX1 me-
tastases have a comparable size in skeletal muscle (Figure 3E).
These data indicate that metabolically active tissue such as skel-
etal muscle can complement the deficiency in PROX1. They also
highlight important differences in metabolism of metastases
versus primary tumors and further underscore a need to better
understand and exploit such differences.
Previous studies documented a critical role of stromal inflam-
mation, extracellular matrix, and chemokine/growth factor
signaling for the successful outgrowth of cancer cells (Chaffer
and Weinberg, 2011; Bhowmick, 2012; Zeelenberg et al.,
2003). Our work reveals a cancer-type-specific mechanism of
metastasis progression by demonstrating that the CRC-specific
Wnt target gene PROX1 increases metabolic fitness of metasta-
tic cancer stem cells. Importantly, all human and mouse models
used in the study carry an activatingmutation inKRAS, which un-
derlies intrinsic or acquired resistance to targeted anti-EGFR
therapies (Van Emburgh et al., 2014). PROX1 deficiency can
therefore override advantages gained through the activation
of KRAS signaling in Wnthigh cancer cells. Thus, targeting of
PROX1 and PROX1-dependent pathways should be further
explored for development of potential treatment approaches of
PROX1+ KRAS mutant, anti-EGFR-resistant CRC metastases.
EXPERIMENTAL PROCEDURES
Human Tumor Analyses
Use of human CRC samples was approved by the Canton of Vaud’s ethics
committee. See Supplemental Experimental Procedures for staining and
tumor sample information.
Bioinformatics Analyses
The correlation analysis of PROX1 expression with cell differentiation, prolifer-
ation, and stem cell markers was based on GSE41258 data set (Sheffer et al.,
2009). We used GSE33112 data set (de Sousa E Melo et al., 2011) to analyze
PROX1 levels in Wnthigh and Wntlow CSCs. See Supplemental Experimental
Procedures for the detailed description. PROX1 and BCL2L15 expression
was analyzed in 230 microsatellite stable colon tumors and 17 normal colon
tissues from The Cancer Genome Atlas (TCGA) data set COAD UNC_Illumina-
GA_RNASeqV2 (TCGA project: http://cancergenome.nih.gov/).
Cell Lines and Culture Conditions
SW620, SW480, and DLD1 (CCL-227, CCL-228, and CCL-221; ATCC) cells
were used for generation of cell lines and spheroids as described in Sup-
plemental Experimental Procedures. ECAR and OCR were measured in
cells cultured for 24 hr prior to analysis according to the manufacturer’s
protocols (SeahorseBio), and all data were normalized to the total protein
content.
Animal Studies
Experiments were approved by the Animal Ethics Committee of the Canton of
Vaud or by the UK Home Office regulations. The complete list of mouse lines,
genotyping, and other procedures are provided in Supplemental Experimental
Procedures.
Staining Procedures
Staining procedures and list of antibodies are provided in Supplemental
Experimental Procedures. Metastases were quantified using staining for hu-
man vimentin or KRT20. We detected cell proliferation for phosphohistone
H3 (Cell Signaling Technology) and apoptosis by staining for cleaved
caspase-3 (CST) or by TUNEL assay (R&D Systems). We used Axiovision Im-
ager.Z1 or Zeiss LSM 510 META scanning confocal microscope for image
acquisition and Bitplane IMARIS Suite 6.3.1 and Adobe Photoshop CS6 for im-
age analyses.
RNA Isolation, Quantitative PCR, Microarray Analyses, and
Western Blotting
We used RNeasy columns (QIAGEN) for RNA isolation and Agilent 2100 Bio-
analyzer (Agilent) for RNA quality control. For transcriptome analyses, we
used RNA from DLD1, DLD1-PROX1, or SW480R cells, transfected with
10 nM PROX1 siRNAs and AllStars control siRNAs (QIAGEN). Affymetrix Hu-
man Gene 1.0 ST arrays (Affymetrix) were used for gene-expression profiling.
See Supplemental Experimental Procedures for list of siRNAs and primers.
We performed RT-PCR analyses on StepOnePlus or 7500-Fast real-time PCR
Systems (Applied Biosystems) with SYBR Green PCR Master Mix (Applied
Biosystems).
For western blotting, proteins were resolved by SDS-PAGE, transferred onto
Immobilon-P, and detected with horseradish-peroxidase-conjugated second-
ary antibodies (Dako) and enhanced chemiluminescence (Thermo Fisher
Scientific).
PROX1 ChIP-Seq and Reporter Analyses
Pools of three independent ChIP experiments and input DNA were used for
sequencing (see Supplemental Experimental Procedures).
ChIP-seq data, generation of BCL2L15 luciferase reporter constructs, and
their analyses are described in Supplemental Experimental Procedures.
(G) BCL2L15 limits growth of metastases. GFP- or BCL2L15-expressing SW620 cells were injected i.v., and metastases were analyzed 30 days later. Staining for
PROX1 (green), EdU (red), and DNA (blue). The scale bar represents 100 mm.
(H) Quantification of metastasis size for data shown in (F). Data are presented as mean ± SEM.
(I) Metastasis incidence. Data are presented as mean ± SEM.
(J) BCL2L15 promotes tumor necrosis and reduces proliferation in metastatic PROX1+ cells. Two-way ANOVA; *p < 0.05; **p < 0.01. Data are presented as mean
± SEM.
(K) Depletion of Bcl2l15 increases clonogenicity of intestinal Apcfl/fl;KrasG12D;Tp53fl/fl;villin-CreERT2 (AKP) organoids. Colonies were quantified at day 15,
following seeding of 3,000 single cells per well, transduced with a nontargeting shRNA (shCtrl) or shProx1. One-way ANOVA; ***p < 0.001. Data are presented as
box and whiskers; Tukey appearance.
(L) Bcl2l15 depletion promotes tumor growth. shBcl2l15, control nontargeting shRNA (shCtrl), or shProx1-transduced organoid were implanted subcutaneously
into NOD-SCIDg/ mice. Two-way ANOVA; **p < 0.01; ***p < 0.001. Data are presented as mean ± SEM.
(M) Target protein expression, proliferation, and apoptosis in organoid-derived tumors. Staining for Prox1 (green), Bcl2l15, EdU or cleaved caspase-3 (red), and
DNA (blue). The scale bar represents 25 mm.
(N) Quantification of cell proliferation in organoid tumors. Data are presented as mean ± SEM.
(O) Quantification of apoptosis in organoid tumors. One-way ANOVA; *p < 0.05; ***p < 0.001. Data are presented as mean ± SEM.
(P) Mutually exclusive localization of PROX1 and BCL2L15 in human CRCmetastases. Staining for PROX1 (green), BCL2L15 (red), and DNA (blue). The scale bar
represents 25 mm.
(Q) BCL2L15 mRNA is reduced in colon tumors and anticorrelates with PROX1 mRNA levels. Heatmap of PROX1 and BCL2L15 mRNA levels in CRC tumors and
normal colon samples.
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Statistical Analyses
Weused Prism5.0 for laboratory data analysis. p value% 0.05was considered
to be statistically significant. Full description of statistical analyses is provided
in Supplemental Experimental Procedures.
ACCESSION NUMBERS
The ArrayExpress accession numbers for the DLD1 or SW480R ± PROX1 mi-
croarray data reported in this paper are E-MTAB-2020 and E-MTAB-2021. The
Gene Expression Omnibus submission accession number for the PROX1
ChIP-seq analysis performed on SW480R cells reported in this paper is
GSE60390. The Cis-Regulatory Element Annotation System output relative
to those data is accessible at http://bcf.isb-sib.ch/data/ragusa_et_al/
PROX1vsInput_hg18.bed and http://bcf.isb-sib.ch/data/ragusa_et_al/.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2014.08.041.
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Figure S1, related to Figure 1. Analyses of PROX1 expression in human and 
mouse CRC. (A, B) PROX1 is preferentially expressed in Wnthigh types of CRC 
tumors. Molecular classification according to (Sadanandam et al., 2013) and 
(Budinska et al., 2013). PROX1 expression (red line) is expressed as log2. CIMP-H, 
CpG island methylator phenotype-high. (C) PROX1 protein is higher in MMR+ CRC 
tumors. Histological score for PROX1 in MMR+ (n=125) and MMR- (n=35) CRC 
samples. Scoring is based on the percentage of strongly nuclear PROX1-positive 
cells, normalized to the total number of cancer cells. Student t-test: ***, P<0.001. 
Mean ± SEM. (D) Examples of PROX1 expression in MMR+ and MMR- tumors. 
Staining for PROX1, ß-catenin (CTNNB1), CMYC, MLH1 and MSH2 (brown), and 
DNA (blue). Scale bar, 50µm. (E) PROX1 mRNA levels in normal colonic mucosa, 
adenoma samples, all CRCs, and those stratified according to their MMR status. 
Dataset by (Sabates-Bellver et al., 2007) was used for the analysis. One-way 
ANOVA, *, P<0.05; **, P<0.01. Mean ± SEM. (F) Correlation of PROX1 mRNA 
with MSI/MSS status in PETACC-3 database for 688 CRC primary tumors (Roth et 
al., 2010). P=1.3e-13. Log. expression values, 1.5xIQR. (G) Example of PROX1- 
primary CRC with corresponding PROX1+ metastases. Staining for PROX1 (brown) 
and DNA (blue). Scale bar, 100µm. (H) Expression levels of PROX1 correlate with 
proliferation of human metastases. Chromogenic staining of serial sections of lung 
metastases for PROX1 and phosphohistone H3 (brown) and DNA (blue). Scale bar, 
200µm. Upper row, low PROX1 expression and proliferation; lower row, high 
PROX1 expression and proliferation. (I) Examples of PROX1 and phosphohistone H3 
scores in two patients. (J) PROX1 levels in human CRC metastases are anti-correlated 
with differentiation marker KRT20. Staining for KRT20 (red), PROX1 (brown) and 
DNA (blue). Scale bar, 50µm. (K) Quantification of Prox1+ cells in the indicated 
subsets of cells in Apcf/f;Lgr5-EGFP-Ires-CreERT2 adenomas. Mean ± SEM. (L) 
Quantification of Prox1+ cells in the indicated subsets of normal small intestinal cells 
in AKP mice. Mean ± SEM. (M) Expression pattern of Prox1, stem/progenitor and 
proliferation markers in AKP intestinal tumors. Prox1 (red), Lgr5, EphB2 and Cd44 
(green), β-Catenin, Krt20 and Ki67 (light blue) and DNA (blue). White arrows 
indicate Prox1+/marker+ cells. White asterisk indicate Prox1-/marker+ cells. Scale bar, 
20µm. (N) Quantification of Prox1+ cells in the indicated subsets of cells of AKP 
tumors. Mean ± SEM. 	  

Figure S2, related to Figure 2. PROX1 promotes colon cancer metastasis. (A) 
SW620 cells, derived from lymph node metastases of colon adenocarcinoma express 
high levels of PROX1.Staining for PROX1 (green) and DNA (blue). Scale bar, 20µm. 
(B) Western blotting for indicated proteins. Parental SW480-A cell line and DLD1 
cells express low levels of PROX1; parental SW480-R cells express high levels. (C) 
Efficient in vitro down-regulation of PROX1 in SW620 shPROX1 cells. Western blot 
for the indicated proteins. (D) PROX1 depletion does not affect growth of primary 
tumors. Student t-test, ns. Tukey appereance. (E) Increased incidence of SW620 shCtr 
metastases. Metastatic foci are identified by staining for human vimentin. One-way 
ANOVA: *, P<0.05; ***, P<0.005. Tukey appereance. (F) Depletion of PROX1 
decreases size of metastases. Individual metastasis size was determined by dividing 
total vimentin+ areas by the number of lesions and normalized to the total surface 
analyzed. Student t-test: *, P<0.05; ***, P<0.005. Tukey appereance. (G, H) 
shPROX1 metastases have decreased proliferation and increased cell death. (G) 
Histology of lung and lymph node SW620 metastases.  Staining for human vimentin 
(brown) and DNA (blue); or vimentin (green), phosphohistone H3 (red) and DNA 
(blue). Arrowheads: necrotic areas. Scale bar 200µm. (H) Comparable apoptosis in 
PROX1- and PROX1+ primary tumors and increased apoptosis in PROX1- metastases. 
TUNEL staining (brown) and DNA (blue). Scale bar, 200µm. (I) Treatment with 
doxycycline reduces PROX1 levels in SW480R-PROX1si cells, but not in the control 
SW480R-GFPsi cells. Western blotting for the indicated proteins. (J) Inducible 
depletion of PROX1 does not affect growth of primary tumors. Dissected tumor 
weight. Student t-test, ns. Tukey appereance. (K) Doxycycline treatment decreases the 
incidence of SW480R/ PROX1si metastases, and reduces individual metastases size. 
Individual metastasis size was determined by dividing the total metastasic areas by 
the number of metastases and normalizing to tissue area analyzed. Student t-test, *, 
P<0.05; **, P<0.01. One-way ANOVA, **, P<0.01. Tukey appereance. (L) 
Doxycycline treatment does not affect metastasis in SW480R/GFPsi cells. Cancer 
cells were identified with human vimentin+ staining. Student t-test and One-way 
ANOVA, ns. Tukey appereance. (M) Microscopic appearance of SW480R metastatic 
lymph nodes in the indicated tumor types. Staining for vimentin (brown), and 
counterstained for DNA (blue). Black arrowheads mark necrotic areas. Scale bar, 200 
µm. 	  

Figure S3, related to Figure 3. PROX1 does not induce EMT, local invasion or 
angiogenesis. (A) PROX1 does not modulate EMT in vitro. Western blotting for 
epithelial marker E-cadherin, mesenchymal marker vimentin, PROX1 and GAPDH, 
in cultured SW620 shCtr or shPROX1 cells and DLD1-PROX1 or DLD1 control 
cells. (B) PROX1 does not affect CRC invasion in vitro. Matrigel invasion assay of 
SW620 shCtr or shPROX1 (left) and DLD1-PROX1 or DLD-1-control (right) cells. 
Invasion is indicated as percentage of transmigrated cells, normalized to the total 
number of plated cells. Student t-test (SW620) and one-way ANOVA (DLD1), ns. 
Mean ± SEM. (C) Absence of gross alterations in the pattern of primary tumor 
invasion in SW620 shCtr and shPROX1 tumors. Staining for PROX1 (pink), active 
caspase-3 (green) and DNA (blue). Orange arrows, invasive strands of cells. White 
arrowheads, necrotic areas. Scale bar, 100µm. (D) Semi-quantitative analysis of 
invasion in tumors. Invasion into indicated tumor sides is expressed as cell budding 
and invasive strands foci number over total tumor areas analyzed. One-way ANOVA, 
ns. Mean ± SEM. (E) Comparable blood vascular density in primary or metastatic 
PROX1+ or PROX1- tumors. Endothelial cells were identified by staining for 
endomucin. Vascular index is expressed as total vessel surface per tumor area. One-
way ANOVA, ns. Mean ± SEM. 	  

Figure S4, related to Figure 4. Effects of PROX1 depletion on growth of CRC 
cells in 3D. (A) Doxycycline treatment does not affect growth of SW480R/PROX1si 
cells under 2D conditions. In vitro growth curves of SW480R/PROX1si cells treated 
with PBS (control, CTR) or doxycycline. Mean ± SEM. (B) PROX1 suppression 
decreases growth of SW480R spheroids. Size of SW480R/PROX1si individual 
spheroids treated with doxycycline or PBS. Two-way ANOVA, ***, P<0.001. Mean 
± SEM. (C) Doxycycline treatment decreases the incidence of SW480R/PROX1si 
spheroids. Total number of spheroids >500µm2. Student t-test, *, P<0.05. Mean ± 
SEM. (D) Suppression of PROX1 reduces growth of tumor spheroids. Microscopic 
phase contrast appearance of SW620-shCtr or shPROX1 spheroids at day 12 (upper 
row) and 15 (middle row). Scale bar, 100µm. Lower row: increased proliferation of 
SW620 shCtr spheroids. Whole mount staining for phosphohistone H3 (red), F-actin 
(green), and DNA (blue). Scale bar, 100µm.  	  

Figure S5, related to Figure 5. PROX1 promotes resistance and metabolic 
adaptation to hypoxia and nutrient deprivation.	   (A) Etoposide induces cell death 
both PROX1+ and PROX1- cells. DLD1 PROX1 or Control, and SW620 shPROX1 or 
shCtr cells were cultured for 72 hours in the presence of 10 or 1µM etoposide (ET) 
and cell number was determined using Cell Titer Blue (CTB) assay. Data of each 
culture condition are normalized to CTB values in untreated cells. One-way ANOVA, 
ns. Mean ± SEM. (B) Depletion of PROX1 in SW620 cells decreases cell number in 
hypoxia and low-nutrient conditions. Cell number was determined by CyQuant assay. 
Two-way ANOVA; **, P<0.01; ***, P<0.001. Mean ± SEM. (C) SW620 shCtr but 
not shPROX1 cells continue to proliferate in hypoxia or low nutrient conditions. 
Proliferating cells were determined by staining for phosphohistone H3. Mean ± SEM. 
(D) SW620 shCtr cell evade apoptosis in hypoxia or low nutrient conditions. 
Percentage of apoptotic cells, as determined by staining for cleaved caspase-3. One-
way ANOVA, comparing same conditions in shCtr versus shPROX1 cells, black *, 
P<0.05; ***, P<0.001; Two-way ANOVA, treatment versus normal culture 
conditions of same cell type, red **, P<0.01 , ***, P<0.001. Mean ± SEM. (E) DLD1 
PROX1 cells cultured in low glutamine have similar glycolysis rates in comparison to 
control cells. Inhibition of mitochondrial respiration with uncoupling agent FCCP 
induces higher glycolysis in PROX1 cells only. (F) Higher oxidative phosphorylation 
in glutamine-starved DLD1 PROX1 cells. (G) Higher glycolysis rates in SW620 
shCtr cells cultured in hypoxia as compared to SW620 shPROX1 cells. (H) Decreased 
oxygen consumption rates in SW620 shCtr and shPROX1 cultured under hypoxic 
conditions. Two-way ANOVA, * P<0.05, ** P<0.005, *** P<0.001; red * PROX1+ 
versus PROX1- cells in indicated condition, black *, significant change of the same 
cell type in switched condition. Mean ± SEM. 

Figure S6, related to Figure 6. Therapeutic potential of targeting PROX1.	   (A) 
PROX1 protein is reduced both in primary tumors and metastases upon administration 
of doxycycline. SW480R/PROX1si cells were implanted into caecum of NOD-scid; 
IL-2Rγ-/- mice and doxycycline was administered 30 day after the implantation, when 
metastases were already detectable. Staining for PROX1 (red), vimentin (green) and 
DNA (blue). White dashed line, tumor margins. White arrows, PROX1+ infiltrated 
cells escaping inhibition. Scale bar, 100µm. (B) Effects of PROX1 depletion in 
established metastases. Two-way ANOVA, **, P<0.01. n=11 per group. Tukey 
appereance. (C) PROX1 depletion reduces size of individual lung and lymph node 
metastases. Tumor cells were identified by staining for human vimentin. Individual 
metastasis size was determined by dividing the total metastasic areas by the number 
of metastases and normalizing to tissue area analyzed. Student t-test, ***, P<0.01. 
Tukey appereance. (D) Chloroquine (CQ) induces enlarged autophagosome in 
hypoxic colon cancer cells. Staining of DLD1 PROX1 and Control cells for the 
autophagosome component LC3B (red) and DNA (blue). Scale bar 25µm. (E) 
Chloroquine (CQ) suppresses PROX1-dependent cell adaptation to hypoxia. 
Quantification of cell proliferation as determined by staining for phosphohistone H3 
in DLD1 PROX1 (P) and Control (C) cells. Mean ± SEM. (F) Autophagy inhibitors 
suppress PROX1+ cell growth in hypoxia. DLD1 or SW620 cells were cultured in the 
absence and in the presence of chloroquine (CQ) or 3-methyl adenine (3-MA) for 72 
hours in normoxia or hypoxic conditions and cell number was determined using Cell 
Titer Blue assay (CTB). Data of each culture condition are normalized to CTB values 
in untreated cells. PROX1- cells appear unaffected because of low proliferation and 
high apoptosis in hypoxic conditions already without treatment. Mean ± SEM. (G) 40 
mg/kg chloroquine treatment does not affect incidence of liver metastases. Mean ± 
SEM. (H) 40 mg/kg chloroquine treatment reduces the size and (I) increases necrosis 
in liver metastases. Metastases >100µm2 were used for quantification. Tumor cells 
were identified by staining for human vimentin. One-way ANOVA, *, P<0.05, ** 
P<0.01, *** P<0.001. Tukey appereance (H). Mean ± SEM (I). (J) Chloroquine 
induces central necrosis in SW620 shCtr liver metastases. Cells were injected into the 
tail vein, and CQ or PBS was administered at day 3 (CQ 3) or 7  (CQ 7) post-
injection. Tumor cells were identified by staining for human vimentin. Black 
arrowheads indicate necrotic areas. Scale bar, 200µm. (K) 10 mg/kg chloroquine 
treatment does not affect the incidence of liver metastases. Metastases >100µm2 were 
quantified. Tumor cells were identified by staining for human vimentin. Student t-test, 
ns. Mean ± SEM. (L) Quantification of phosphohistone H3+ cells in liver metastases 
in mice treated with 10 mg/kg CQ or PBS at tumor-stromal interface, metastasis 
center and globally. Mean ± SEM. (M) Quantification of PROX1+ cells in liver 
metastases, and (N) quantification of vascular density. Blood vessels were identified 
by staining for endomucin. Two-way ANOVA, *, P<0.05; **, P<0.01; ***, P<0.001. 
Mean ± SEM. (O) Comparable apoptosis rates in PROX1- and PROX1+ primary 
tumors and high apoptosis in PROX1- metastases. Apoptosis was quantified in 
SW620 shCtr and shPROX1 tumors by staining for cleaved capase-3. Two-Way 
ANOVA, ***, P<0.001. Mean ± SEM. (P) Autophagy inhibition does not affect 
growth of primary tumors. SW620 PROX1+ or PROX1- cells were injected 
intracecally and mice were treated with PBS or 10 mg/kg/day CQ starting at day 9th 
post injection. Tukey appereance. (Q) Chloroquine treatment does not affect number 
of metastatic foci in orthotopic model. One-Way ANOVA, * P<0.05. Mean ± SEM. 
(R) Chloroquine treatment does not affect tumor vascular density, as determined by 
staining for endomucin. Two-Way ANOVA, ns. Mean ± SEM. 

Figure S7, related to Figure 7. Molecular mechanisms of PROX1 in colorectal 
cancer. (A) Outline of experiments for the identification of PROX1 direct target 
genes. (B) PROX1 preferentially binds near PROX1-repressed genes. Cumulative 
distribution function of binding site intensity (as log2 fold enrichment over input) for 
PROX1, stratified by the set of genes up- or down-regulated by PROX1 or a reference 
set of stable genes in the corresponding knock-down experiment. P-values are relative 
to Kolmogorov-Smirnow tests of equal distribution as the reference. (C, D)  
Validation of microarray analysis. qPCR analysis for selected genes in SW480R 
transfected with two different PROX1 siRNAs and DLD1 PROX1+ or PROX1- cells. 
Two-Way ANOVA, ***, P<0.001. Mean ± SEM. (E) Validation of TNFRSF9, 
BCL2L15 or CAV1 expression in SW620 TNFRSF9, BCL2L15, CAV1 or control 
GFP cell lines. qPCR analysis of the indicated transcripts. Mean ± SEM. (F) 
Overexpression of PROX1 targets BCL2L15 and CAV1, but not TNFRSF9, mimics 
the effects of PROX1 depletion in PROX1+ SW620 cells cultured in hypoxia. SW620 
transduced with shNT, not targeting, or shPROX1 lentiviruses were used as negative 
and positive controls. Cell number was determined by CyQuant DNA based assay 
after 72 hours. Two-way ANOVA, **, P<0.01. Mean ± SEM. (G) Inverse localization 
of Prox1 and Bcl215 protein in AKP intestinal tumor. Staining for Bcl2l15 (red), 
Prox1 (green), and DNA (blue). Scale bar, 50µm. (H) Prox1 depletion induces 
Bcl2l15 expression in AKP organoids in vitro. mRNA levels at day 5 post 
transduction. Student t-test, *** P<0.001. Mean ± SEM. (I) qPCR validation of Prox1 
or Bcl2l15 suppression in AKP shCtrl, shProx1 and shBcl2l15 after puromycin 
selection. mRNA levels. Student t-test, *** P<0.001. Mean ± SEM. (J) shBcl2l15  
AKP organoids  form larger tumors. shProx1 and shCtrl organoids were used as 
controls. One-Way ANOVA, *** P<0.001. Tukey appereance. (K) The majority of 
BCL2L15+ cells in human colorectal cancer metastases does not express PROX1. 
Lung metastasis, n=5. Student t-test, ***, P<0.001. Mean ± SEM. (L) PROX1 
binding sites in BCL2L15 locus, used for the luciferase reporter analyses. (M) 
PROX1 represses the activity of BCL2L15 enhancer 4. SW480A25 cells were 
transfected with the reporters or control pTAL vector plasmid and an expression 
vector for PROX1. Luciferase activity was measured 36 hours after the transfection, 
and is expressed as fold increase over the pTAL control values. Two-Way ANOVA, 
*** P<0.001. Mean ± SEM. 	  
Potential target genes of PROX1  in DLD1 and SW480R cells
Genes 
repressed by 
PROX1 in two 
lines
Fold change in 
SW480R-siPROX1 
1 
Fold change in 
SW480R-siPROX1 
2 
Fold change in 
DLD1 cells
PROX1 binding in 
50Kb upstream to 
50Kb downstream
ABAT 2.332721376 2.223949456 1.650478677 +
ANXA1 2.314210343 2.29464345 1.905916613 +
ANXA6 1.838318189 2.27073681 1.631852884 +
AP1S2 2.657488595 2.460179361 1.757789726 +
BCL2L15 2.540603961 2.354974601 4.118251678 +
C3orf52 1.566523595 1.574714186 1.598285901 +
CAV1 2.041578442 2.91603897 2.323729278 +
CDRT1 1.973770158 1.965092876 2.432281991 +
CLIC5 1.571001437 1.78584083 2.280835659 +
CYBRD1 2.769060356 1.526339613 1.501348083 +
EMP1 3.680347519 3.413536078 1.70935909 +
EPAS1 6.280913932 4.188604014 1.965151447 -
GBP1 2.084760999 1.846328166 1.832850355 +
GBP3 1.863263871 1.724520167 2.4788552 +
GPRC5A 3.266811021 3.568735553 1.552097836 +
HPGD 1.69985419 1.953144922 1.539682093 +
HSD3B1 2.358187611 1.695748245 1.524467612 +
IGFL2 3.201749638 2.005281117 1.807112096 -
IQGAP2 2.336867604 3.422090705 3.492051898 +
ITGA2 2.617969882 2.910492904 1.724110212 +
ITGA3 2.362826176 2.853847017 1.501348603 +
KIAA0040 2.634706942 2.820649686 1.504893612 +
LST-3TM12 2.672372281 2.875858115 1.885372382 +
MID1 2.470302984 2.345999978 1.502697378 +
MOSPD1 2.246864308 2.478968604 1.963937475 +
MPP1 2.321544604 1.544007756 2.867735568 +
MT1G 1.526823715 1.981310515 1.575495354 +
MT2A 1.468379624 1.741433039 1.825776284 +
NOSTRIN 3.163697145 3.063008775 1.714232744 +
PBX3 2.203468084 1.90449698 1.855082052 +
PHLDB2 2.280591415 2.54587573 1.624053321 +
PPP4R1L 1.761186267 1.753157366 1.728356109 +
RGL1 1.555617101 1.546234893 1.734921035 +
ROR1 1.747773218 1.581259887 1.505649537 +
SCEL 1.879505973 2.029396832 3.321397747 +
SCML1 1.822943061 2.51213762 1.519873234 -
SEMA3C 5.200343784 6.227935486 2.458712417 +
SERPINA1 1.68752924 1.611616521 1.540034318 +
SERPINE2 1.807806793 2.420141666 1.541170525 -
SLC7A7 7.153719248 4.938549943 3.216718078 +
SLCO1B3 5.526405792 6.019929118 2.100467553 -
TNFAIP3 1.889701026 2.189731529 1.791377635 -
TNFRSF9 2.927002545 3.675938169 2.040955179 +
TRIM16 2.076082104 2.439234566 1.502473973 +
VGLL3 1.774237325 2.024405782 3.72883252 -
ABAT, BCL2L15, CAV1, IQGAP2, SEMA3C, SLC7A7 and TNFRSF9 are the genes with fold change greater 
than 2 folds, and have PROX1 binding in their vicinity
	  Table S1, related to Figure 7. Potential target genes of PROX1 in DLD1 and 
SW480R cells. Combined targets of the microarrays presented in Tables S2 and S3. 
 
Table S2, related to Table S1 (separated file). Genes differentially expressed in 
SW480R after PROX1 knock-down. Microarray. Cutoff 1.5 fold change, 
FDR<0.05. See also Table S1.  
 
Table S3, related to Table S1 (separated file). Genes differentially expressed in 
DLD1-PROX1 vs. DLD1 control cells. Microarray. Cutoff 1.5 fold change, 
FDR<0.05. See also Table S1. 
 
  
	  Supplemental Experimental Procedures 
 
Human tumor samples used for the analysis  
The three primary tumor and metastases series were analyzed: 15 primary tumors, 14 
lymph nodes and 8 liver metastases (series 1, scored by H.B.); 13 primary tumors, 6 
liver metastases, 14 lung metastases, 1 brain metastasis, 1 adrenal gland metastasis, 1 
ovarian metastasis, 1 bronchial metastasis and 2 lymph nodes (series 2, scored by 
I.L.); 5 primary tumors and 5 lung metastases (series 3, scored by I.L.), see the table 
below for more detailed information. For markers colocalization, slides were also 
stained for EPHB2, CD44, BMI1 and Keratin 20. Staining for phosphohistone H3 
protein was performed on 7 primary tumors, for which at least one lung and liver 
metastases were available. Lymphatic endothelial cells, which high levels PROX1 
(Wigle and Oliver, 1999) were used as an internal positive control. The score 
represents the percentage of cancer cells with nuclear PROX1 higher or comparable 
to lymphatic endothelial cells on the same slide. A global percentage ≤5% was 
considered as negative. 
	   
Metastases	  N°	   	  	   Metastasis	   	  	   	  	   Analysis	   Analysis	  
Series	  1	   Patient	  ID	   TNM	  	   Liver	   Lung	   Lymph	  N.	   Others	   PH3	  	   SC	  
1	   H1001332	   T3	   1	   0	   1	   -­‐	   -­‐	   -­‐	  
2	   H1007751	   T3	   1	   0	   1	   -­‐	   -­‐	   -­‐	  
3	   H0904002	  	   T3	   1	   0	   0	   -­‐	   -­‐	   -­‐	  
4	   H0909081	   T3	   1	   0	   1	   -­‐	   -­‐	   -­‐	  
5	   H0904539	   T3	   1	   0	   0	   -­‐	   -­‐	   -­‐	  
6	   H0904001	   T3	   1	   0	   0	   -­‐	   -­‐	   -­‐	  
7	   H0910992	   T3	   1	   0	   0	   -­‐	   -­‐	   -­‐	  
8	   H0912652	   T3	   1	   0	   0	   -­‐	   -­‐	   -­‐	  
9	   H0915774	   T3	   0	   0	   2	   -­‐	   -­‐	   -­‐	  
10	   11H03026	   T3	   0	   0	   2	   -­‐	   -­‐	   -­‐	  
11	   10H7110	   T3	   0	   0	   2	   -­‐	   -­‐	   -­‐	  
12	   09H13383	   T3	   0	   0	   2	   -­‐	   -­‐	   -­‐	  
13	   09H12474	   T3	   0	   0	   1	   -­‐	   -­‐	   -­‐	  
14	   09H7432	   T3	   0	   0	   1	   -­‐	   -­‐	   -­‐	  
15	   08H1305	   T3	   0	   0	   1	   -­‐	   -­‐	   -­‐	  
Series	  2	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
1	   4	   T1M0N0	   0	   2	   0	   -­‐	   Yes	   -­‐	  
2	   5	   T3M0N0	   0	   0	   1	   -­‐	   -­‐	   -­‐	  
3	   6	   T3M1N1	   0	   1	   0	   Brain	   -­‐	   -­‐	  
4	   7	   T2M0N0	   0	   1	   0	   -­‐	   -­‐	   -­‐	  
5	   8	   T3M0N0	   1	   1	   0	   -­‐	   Yes	   -­‐	  
6	   15	   T3M0N0	   0	   1	   0	   Bronchial	   -­‐	   -­‐	  
7	   17	   T3M0N1	   1	   1	   0	   -­‐	   Yes	   -­‐	  
8	   18	   T3M1N0	   0	   1	   1	   -­‐	   -­‐	   -­‐	  
9	   19	   T1M0N0	   1	   1	   0	   -­‐	   Yes	   -­‐	  
10	   22	   T3M0N0	   1	   1	   0	   -­‐	   Yes	   -­‐	  
11	   23	   T3M2N1	   1	   3	   0	   -­‐	   Yes	   -­‐	  
12	   27	   T2M0N0	   0	   0	   0	   Adrenal	  Gland	   -­‐	   -­‐	  
13	   29	   T4M2N1	   1	   1	   0	   Ovary	   Yes	   -­‐	  
Series	  3	   	  	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
1	   Case1	   T3N1	   0	   1	   0	   -­‐	   -­‐	   Yes	  
2	   Case2	   T3N0	   0	   1	   0	   -­‐	   -­‐	   Yes	  
3	   Case3	   T3N0	   0	   1	   0	   -­‐	   -­‐	   Yes	  
4	   Case4	   T3N1	   0	   1	   0	   -­‐	   -­‐	   Yes	  
5	   Case5	   T2N0M1	   0	   1	   0	   -­‐	   -­‐	   Yes	  
 
Table S4, related to Figure 1. Human tumor and metastasis series samples used. 
The samples are related to data presented in Figures 1 and S1. 
 
 
	  Bioinformatics analyses of published data sets. 
Statistical significance of differences in correlation values between lung metastasis 
and primary tumors was assessed by a permutation test. To study the expression of 
genes or gene signatures, primary tumor and lung metastasis samples were divided in 
3 categories by tertiles of PROX1 expression level (high, medium and low). The 
number of samples per group were: Lung 7 high, 6 med, 7 low; Primary 63 high, 61 
med, 62 low. Average expression of single genes or signatures in spider graphs was 
plotted in log scale. The grey inner circle delimits the level of the average expression 
across the 6 categories. 
 
Analyses of PROX1 expression in CRC subtypes 
Budinska et al. reported that unsupervised clustering based on gene modules lead to 
distinguish five different gene expression CRC subtypes (A to E, (Budinska et al., 
2013)). We also applied the subtype system of (Sadanandam et al., 2013) to the 
PETACC-3 (Pan-European Trials in Alimentary Tract Cancers) database, containing 
histopathological evaluation, mutation analysis and MSI status analysis for 688 stage 
II/III human CRC primary tumors (Roth et al., 2010). Gene expression with the 
ALMAC Colorectal Cancer DSA platform (Craigavon, Northern Ireland), a 
customized Affymetrix chip with 61,528 probe sets mapping to 15,920 unique Entrez 
Gene IDs, was reported in (Popovici et al., 2012). In this case, Sadanandam et al. 
algorithm separated tumors into stem-like, Goblet cells and inflammatory subtypes, 
while transient-amplifying and enterocytes signatures remained merged together 
(N.Zangger, unpublished observation). Wilcoxon rank test was computed to assess 
statistical significance.    
 
	  Correlation of PROX1 levels with MSS and MSI status in CRC 
For the analysis of PROX1 mRNA levels in human normal colon, colorectal 
adenomas, and MMR+ and MMR- CRCs and cell lines, expression data were 
extracted from a published microarray dataset (Sabates-Bellver et al., 2007). The 
tissue groups were composed of 32 normal mucosae samples, 32 adenomas, 13 
MMR+ CRCs and 12 MMR- CRCs. The CI of the qPCR was 0.05. For the analysis of 
PROX1 protein level in MMR+ vs. MMR- tumors, 160 human CRCs samples were 
stained for PROX1, ß-catenin (CTNNB1) or CMYC, and scored by F.B. The MMR 
status was evaluated by staining adjacent sections for the mismatch repair MLH1 or 
MSH2 proteins. Global correlation of PROX1 expression levels with the 
microsatellite status and other pathological and molecular parameters was performed 
using the PETAC-3 database, which contains histopathological evaluation, mutation 
analysis, and MSI or MSS status for 688 human stage II/III CRCs (Roth et al., 2010). 
Gene expressions was measured on the ALMAC Colorectal Cancer DSA platform 
(Craigavon, Northern Ireland), a customized Affymetrix chip with 61,528 probe sets 
mapping to 15,920 unique Entrez Gene IDs, as described in (Popovici et al., 2012). 
MSI status was determined using a panel of 10 mononucleotide and dinucleotide 
microsatellite loci by polymerase chain reaction amplification of normal/tumor DNA 
pairs. MSI was graded as high (MSI-H) or low (MSI-L) (Roth et al., 2010). 
 
Production of cell lines and cell culture procedures 
shProx1 or shBcl2l15 intestinal Apcf/f;KrasG12D;Tp53f/f organoids were produced by 
transducing cells with lentiviruses encoding  PROX1shRNA and control scrambled 
shRNA in pLL3.7 backbone, described previously (Petrova et al., 2008). Organoids 
were dissociated and GFP+ cells sorted and plated for the clonogenic assay. 
	  Alternatively, mouse scrambled (TRC PLKO.1), mouse Prox1 (CloneId, 
TRCN0000070725, Thermo Scientific) or mouse Bcl2l15 shRNA (1RMM4431-
200308443, Thermo Scientific) were used for organoid transduction, which were then 
selected with puromycin (3µg/ml) for 10 days before dissociation and clonogenic 
assay or transplantation. SW620 shPROX1 and shCtr cells were produced by 
transducing cells with recombinant lentiviruses expressing PROX1shRNA and 
control scrambled shRNA, described previously (Petrova et al., 2008). For target gene 
overexpression, cDNAs were subcloned into lentiviral vector pSD44 and used for the 
productition of stably transduced pools. SW480A, SW480R/PROX1si and 
SW480R/GFPsi cell lines were described previously (Petrova et al., 2008). For 
overexpression experiments, PROX1 wild type and mutated (N625A) PROX1 cDNAs 
(Petrova et al., 2002) were subcloned into lentiviral vector pSD44, DLD1 cells were 
transduced with PROX1, PROX1mut or control lentiviruses and pools of cells were 
produced using puromycin selection.  Alternatively, individual DLD1 clones were 
generated using stable transfection of PROX1-pAMC and PROX1N625A-pAMC 
plasmids (Petrova et al., 2002), followed by selection in 250µg/ml geneticin (Gibco). 
Primary tumor growth and formation of metastases was similar in pools and 
individual clones. To facilitate detection, cells were tagged with firefly luciferase 
(DLD1 or SW480R cells), or EGFP (SW620 cells). All cell lines were monitored 
routinely for PROX1 expression level by Western blotting, and discarded and freshly 
thawed every 4 months, or earlier if notable changes in PROX1 expression were 
observed. 
 
For clonogenic assay, cell were isolated after 4 days induction with tamoxifen 
1mg/g/day (Sigma) from the intestinal epithelium of Apcf/f;KrasG12D;Tp53f/f;villin-
	  CreERT2 mice as described (Sato et al., 2011) and transduced. For lentiviral 
transduction, 1x105 dissociated AKP cells were transduced with the control, Prox1 or 
Bcl2l15 targeting shRNAs. The transduction was performed under spinning for 1 
hour, plus 6 hours at 37°C with 5%CO2, followed by a recover in Matrigel (Corning, 
356231) for 3 days. For selection, the cells were either sorted by FACS to isolate 
GFP+ transduced cells or maintained in 3µg/ml puromycin in DMEM/F12, 1x 
Glutamax, Hepes 0.01M, B27 and N2 1x (Gibco). In all cases, knock-down was 
confirmed by qPCR and staining. For the clonogenic assay, the organoids were 
dissociated, 3000 single cells/well were plated in 50µl Matrigel and cultured for 15 
days in Advanced DMEM/F-12 (Gibco) with 1x N-2 and B-27 (Gibco), glutamine 1% 
and Hepes 0.01M (Gibco) before quantification.  
 
SW620 cells were maintained in complete RPMI and 15 µg/ml Puromycin (Sigma). 
SW480R cells were maintained in 50 µg/ml Zeocin (Invitrogen) and 10 µg/ml 
Blasticidin (Gibco) and complete RPMI. For western blot analysis we plated 4x105 on 
6 well plate dishes (final protein concentration measured with BCA assay, Roche), for 
RNA extraction 2x106 cells on p100 petri dishes, for cell stainings 2x105 cells on 
coverslips inserted in 24well plates, or 0.5x105 cells on 8 well chambers (Costar), for 
Trypan Blue counting 5x104 cells on 48 well plates, and for cell titer blue (CTB, 
Promega), and CyQuant NF analysis (Invitrogen) 6x103 cells on 96 well plates. RNA 
and proteins were isolated at 12, 24 and 48 hours.  
 
For the analysis of spheroids, 3.5x103 cells were seeded in the MMP-Degradable 
synthetic extracellular MT3D Matrix functionalized with RGD peptides (QGelBio) 
and cultured for 21 days. For spheroid growth quantification 5 random pictures were 
	  acquired from every well using a phase contrast inverted microscope (Axio 
Observer.Z1). At the end of the experiment, the disks were incubated for 1h in 
200µM pimonidazole (Hypoxyprobe™-1 kit, HPI), washed twice in cold PBS, fixed 
for 4 hours in 4% PFA and processed for whole mount staining or embedded in OCT 
and sectioned for immunohistochemical staining. Images of spheroids were acquired 
using a Zeiss LSM 510 Meta inverted confocal microscope. For TUNEL+ cell 
quantification cells were counted and normalized by the total number of DAPI+ cells 
in single sections. 15 spheres or 3 slides from different depths were used for every 
cell type. For phosphohistone H3+ quantification 10 entire spheres were reconstructed 
with Z stacks images per condition. 
 
Cell invasion assays were performed using 5x104 cells/well in 24-well plates with 
8µm pore size inserts (Costar, 6.5mm diameter, 8µm pore size) uncoated or coated 
with 2mg/ml or 3.5mg/ml Matrigel for DLD1 or SW620 cells, respectively. Complete 
RPMI with 10% FBS was used as chemo-attractant after 24 hours starvation. Each 
condition was done in triplicate, and 3 pictures from every membrane were used for 
quantification. Similar results were observed in two independent experiments.  
 
For hypoxia and nutrient deprivation experiments, the cells were incubated in a 
hypoxic chamber (Billups-Rothenberg) in 0.1% O2 or in normoxia. DMEM with no 
glucose and pyruvate (Gibco 31966-021), DMEM without glutamine and pyruvate 
(Gibco 11966-025) or DMEM with glutamine and pyruvate (Gibco 11960-044) 
supplemented with 10% FBS were used as culture media. After 72 hours, live cell 
number was determined using CyQuant NF (Invitrogen) DNA-based assay. 
	  Chloroquine (CQ, 5µM), 3–methyadenine (3-MA, 1mM), or etoposide were added 12 
hours after plating.  
 
Animal experiments. 
We used 8 to 12 week-old NOD-scid; IL-2Rγ-/- mice for tumor xenograft experiments. 
The Apcfl/fl mice (Sansom et al., 2004; Shibata et al., 1997) were crossed with Lgr5-
EGFP-CreERT2 mice (Schepers et al., 2012) or KrasLsl-G12D (Jackson et al., 2001), 
Tp53fl/fl (Marino et al., 2000) and villin-CreERT2 mice (el Marjou et al., 2004) to 
obtain Apcfl/fl;Lgr5-EGFP-CreERT2 or Apcfl/fl;KrasLsl-G12D;Tp53fl/fl;villin-CreERT2 
(AKP) animals. To generate adenomas and tumors for histological analysis, in Apcfl/+; 
Lgr5-EGFP-CreERT2 and Apcfl/+;KrasLsl-G12D;Tp53fl/fl;villin-CreERT2 mice, the Cre 
recombinase was activated by a single 1mg/20g mouse i.p. injection of tamoxifen. 
The tumors were analyzed after 24 days (n=4), and mice were injected i.p. with EdU 
(Invitrogen) 2 hours prior to sacrifice.  
 
In order to obtained fresh intestinal tumorigenic organoids to culture in vitro, 2 
Apcfl/fl;KrasLsl-G12D;Tp53fl/fl;villin-CreERT2 mice were injected daily with tamoxifen 
1mg/20g. After 4 days from the first injection, the intestinal crypts were isolated and 
cultured in Matrigel (Corning, 356231) as described previously (Sato et al., 2011).  
 
For orthotopic models, 1x106 cells suspended in 25µl RMPI containing 33% Matrigel 
(BD) were injected in caecum as previously described (Cespedes et al., 2007; Zaric et 
al., 2012), using a 50µl 28G syringe (Hamilton). When indicated, tumor growth was 
monitored by in vivo bioluminescence after i.p. Injection of 1.5mg/g luciferin 
(Biosynth), using IVIS Lumina II (Xenogen). PROX1+ vs. PROX1- luciferase-
	  transduced cells had similar level of luciferase activity in vitro (data not shown). For 
inducible knockdown experiments, SW480R/PROX1si and SW480R/GFPsi lines, 
which express PROX1 or GFP targeting shRNA upon doxycycline addition, were 
used (Petrova et al., 2008). Doxycycline hyclate 2.5mg/ml (Sigma) was administered 
in drinking water supplemented with 10% sucrose at the day of tumor implantation. 
Control group mice received water with 10% sucrose. For PROX1 suppression in 
established metastases, a group of SW480R/PROX1si injected mice were randomized 
at day 30 to receive doxycycline or sucrose only. The time point was selected because 
a stable bioluminescent signal from metastases, determined as two consecutive 
positive measurements in 7 days, was observed in every mouse. At the time of 
sacrifice ex vivo bioluminescence (DLD1, SW480R) or EGFP fluorescence (SW620) 
was analyzed in organs and in primary tumor using IVIS Lumina II or Leica M205FA 
stereomicroscope.  For ex vivo bioluminescence mice were injected with luciferin 15 
minutes prior to sacrifice and dissected organs were immersed in PBS containing 
0.15mg /ml of luciferin. 
 
For the lung colonization assay, mice survival analysis and CQ treatment, 1x105 
SW620 shPROX1 or shCtr cells in 100µl PBS were injected into tail vein (n=11-12 
per group). For lung colonization assay mice were sacrificed after 2.5 and 7 days, 
perfused intracardially with PBS and tissues were prepared and analyzed as described 
above. For the survival study, mice were sacrificed when becoming moribund 
according to institutional guidelines. For CQ treatment, mice were randomized at day 
3 or 7 after tumor cell injection to receive 40 or 10 mg/kg CQ or PBS I.P. daily. After 
orthotopic implantation, 10mg/kg/day treatment has been followed, starting from day 
15. 
	   
For intestinal organoid implantation, organoids were dissociated and plated in 
matrigel at 6000 cells density. After 3 days in culture, the organoids were collected 
from Matrigel with a cell recovery solution (Corning), stained with trypan blue and 
counted. The spheres were then resuspended in Matrigel/advanced DMEM/F12 
(50/50), and 50 spheroids/mouse were implanted with a 20G needle.  
 
Staining procedures and list of primary antibodies. 
Tissues were fixed in 4% paraformaldehyde (PFA) and embedded in paraffin. 5µm 
deparaffinized sections were subjected to heat-induced epitope retrieval (High/Low 
pH Retrieval solution, DAKO). qGel disks containing spheroids were fixed in 4% 
PFA and processed for whole mount staining or embedded in OCT to obtain 6µm 
frozen sections. Frozen sections were fixed in -20°C cold 50% MetOH-50% Acetone 
(Fluka). Cultured cells were fixed with 4% PFA and permeabilized with 0.5% Triton 
X-100.  Alexa Fluor fluorochrome-conjugated secondary antibodies (Invitrogen) were 
used in fluorescent stainings; biotinylated IgG (Vector) were used together with the 
TSATM kit (PerkinElmer) for chromogenic detection.  
 
The following antibodies and dyes were used for staining and Western blot analyses: 
rabbit anti-human BCL2L15 (Atlas antibodies); mouse anti-human BMI1 (Abcam); 
rabbit anti-activated Caspase 3 (Asp175, Cell Signaling); rat anti-mouse CD44 (BD 
PharmigenTM); rat anti-mouse endomucin (eBioscience), goat anti-mouse EphB2 
(AF467, R&D Systems), FITC-conjugated phalloidin (Invitrogen), rabbit anti-GFP 
(ab290, Abcam); mouse anti-human Glut1 (SPM498, Thermo Scientific); rabbit anti-
human HIF-1α (10006421, Cayman); mouse anti-human Ki67 (BD PharmigenTM);   
	  rabbit anti-mouse Keratin 6 (Covance); mouse anti-human Keratin 20 (Ks20.8, 
Dako); rabbit anti-human LC3B (ab51520, Abcam); rabbit anti-human lysozyme 
(Dako); rabbit anti–human phosphohistone H3 (Ser10 D2C8, Cell Signaling), rabbit 
anti-pimonidazole adducts (HPI, 4.3.11.3, Hypoxyprobe) ; goat anti-human PROX1 
(AF2727, R&D), rabbit anti-human PROX1 (Abcam); TUNEL (4815-30-K, 
Chromogenic R&D Systems Ready Kit); mouse anti-human Vimentin (V9, 
DakoCytomation); mouse anti-human β-Catenin (14, aa.571-781, BD Transduction 
LaboratoriesTM); EdU detection kit (Click It, Invitrogen);  mouse anti-human ß-actin 
(C11, Sigma-Aldrich), mouse anti-human GAPDH (G9545, Sigma-Aldrich); mouse 
anti-human E-Cadherin (24E10, Cell Signaling). 
 
Gene expression profiling analysis. 
The following PROX1 siRNA were used for silencing: 5’-CCG AGU GCG GCG 
AUC UUC AAG AUA U-3’ (PROX1HSS108596, Invitrogen), 5’-GGC CUA CUA 
UGA GCC AGU UUG AUA U-3’ (PROX1HSS108597, Invitrogen). At least 90% 
downredulation of PROX1 protein was observed by Western blot analysis by either 
PROX1 siRNA but not the control siRNA (not shown) at the time of RNA collection. 
Affymetrix Human Gene 1.0 ST arrays (Affymetrix) were hybridized with 2.7µg of 
biotinylated target at 45°C for 17 hours washed and stained according to the protocol 
described in Affymetrix GeneChip® Expression Analysis Manual (Fluidics protocol 
FS450_0007). The arrays were scanned using the GeneChip® Scanner 3000 7G 
(Affymetrix) and raw data was extracted from the scanned images and analyzed with 
the Affymetrix Power Tools software package (Affymetrix). All statistical analyses 
were performed using the high-level interpreted statistical language R and various 
Bioconductor packages (http://www.bioconductor.org). Hybridization quality was 
	  assessed using the Expression Console software (Affymetrix). Normalized expression 
signals were calculated from Affymetrix CEL files using the quantile normalization 
method. Differential hybridized features were identified using Bioconductor package 
“limma” that implements linear models for microarray data (Smyth, 2004). The P 
values were adjusted for multiple testing calculating false discovery rates (FDR) with 
the Benjamini and Hochberg’s method (Klipper-Aurbach et al., 1995). Differentially 
expressed genes were identified by FDR lower than 0.05 and fold change greater than 
1.5. Microarray data are deposited in ArrayExpress. 
 
  
	  qPCR analyses 
Analysis of gene expression was carried out using the comparative Ct (ΔΔCt) method 
as described by the manufacturer (Fold change 2-ΔΔCt). 
List of primers used 
ABAT fwd: gac agg gac acc ctt tgc 
ABAT rev: gaa gtc gag cag aca ccc a 
ANXA6 fwd: ctg gtt tgg cca tgg tct c 
ANXA6 rev: gtt gct gct ggg cta acg ASCL2	  fwd:	  ctc	  gcc	  ctc	  ccg	  cgg	  ttc	  tt	  ASCL2	  rev:	  cca	  gca	  gtg	  tcc	  ctc	  cag	  cag	  Ascl2	  fwd:	  aag	  cac	  acc	  ttg	  act	  ggt	  acg	  Ascl2	  rev:	  aag	  tgg	  acg	  ttt	  gca	  cct	  tca 
BCL2L15 fwd: aac cat taa ggg aca gac agg a 
BCL2L15 rev: gcc acc tgt ccc act act tc Bcl2l15	  fwd:	  aca	  ggc	  agg	  aag	  tac	  tgt	  act	  caa	  Bcl2l15	  rev:	  atg	  ccc	  gtc	  acg	  tag	  tta	  gc 
CAV1 fwd: tcc ctt ctg gtt ctg caa tc 
CAV1 rev: cga gaa gca agt gta cga cg EPHB2 fwd:	  aga	  aac	  gct	  aat	  gga	  ctc	  cac	  t	  EPHB2 rev:	  gtg	  cgg	  atc	  gtg	  ttc	  atg	  tt	  EphB2	  fwd:	  gcg	  gct	  acg	  acg	  aga	  aca	  t	  EphB2	  rev:	  ggc	  taa	  gtc	  aaa	  atc	  agc	  ctc	  a 
GPRC5A fwd: cat ttt cag ctg cag aac ca 
GPRC5A rev: gag gca aac tgt tcc cgt ag 
IQGAP2 fwd: att cag tgg ttg gtg gca a 
IQGAP2 rev: tct gca gag gag atg gat ga LGR5	  fwd:	  ctc	  cca	  ggt	  ctg	  gtg	  tgt	  tg	  LGR5	  rev:	  gag	  gtc	  tag	  gta	  gga	  ggt	  gaa	  g	  Lrg5	  fwd:	  cct	  act	  cga	  aga	  ctt	  acc	  cag	  t	  	  Lrg5	  rev:	  gca	  ttg	  ggg	  tga	  atg	  ata	  gca	  RNF43	  fwd:	  cat	  cag	  cat	  cgt	  caa	  gct	  gga	  RNF43	  rev:	  tta	  ccc	  cag	  atc	  aac	  acc	  act	  	  Rnf43	  fwd:	  tcc	  gaa	  aga	  tca	  gca	  gaa	  cag	  a	  Rnf43	  rev:	  gga	  ctg	  cat	  tag	  ctt	  ccc	  ttc 
TNFRSF9 fwd: ctt ctt ctg gaa atc ggc ag 
TNFRSF9 rev: acg ctc cgt ttc tct gtt gt 
GAPDH fwd: aac gtg tca gtg gtg gac ctg acc t 
GAPDH rev: gtc gtt gag ggc aat gcc agc ccc a 
18S fwd: agg aat tcc cag taa gtg cg  
18S rev: gcc tca cta aac cat cca a 
 
 
  
	  PROX1 ChIP-seq SW480R	  cells	  were	  cross-­‐linked	  with	  formaldehyde,	  chromatin	  was	  fragmented	  using	   SimpleChIP	   Enzymatic	   Chromatin	   IP	   Kits	   (Cell	   Signaling)	   and	  immunoprecipitated	   using	   goat	   anti–human	   PROX1	   antibody	   (R&D	   Systems)	  complexed	  with	  protein	  G	  Sepharose.	  10ng of ChIP sample was quantified using the 
Qubit fluorometer (Invitrogen) and DNA were prepared using the ChIP-Seq Sample 
Preparation Kit (Illumina) according to the manufacturer’s protocol. Libraries were 
sequenced on the Illumina Genome Analyzer IIx using the Single-Read Cluster 
Generation Kit v4 and 38 Cycle Sequencing Kit v4.  Data were processed using the 
Illumina Pipeline Software v1.60. The aligned sequences were generated using the 
ELAND module within the Illumina Genome Analyzer Pipeline Software, v1.3 
(Illumina, Inc.) and mapped to the assembly 18 of human genome. Transcription 
factor binding sites were identified using SISSRs (Site Identification from Short 
Sequence Reads) (Jothi et al., 2008). To reduce false positive calls, DNA input was 
used as a control channel in SISSRs.	   CEAS	   (Ji	   et	   al.,	   2006)	   was	   used	   to	   	   detect	  nearest	  Ref	  Seq	  genes	  and	  position	  of	  binding	  sites,	  as	  indicated	  in	  the	  main	  text.	  
 
BCL2L15/PROX1 correlation statistical analysis 
230 MSS primary tumors and 17 normal tissues (TCGA	   database	   project:	  http://cancergenome.nih.gov/)	   were analyzed. Two-sample Wilcoxon test on 
normal tissue versus CRC was significant for both genes (PROX1, P=4.45e-08; 
BCL2L15 P=2.25e-06). Spearman correlation between the two genes was not 
significant in normal tissue (P=0.63) due to the absence of PROX1 expression, but 
significant for tumor samples (P=1.8e-04). 
 
  
	  Generation of BCL2L15 reporters and luciferase assay 
To generate BCL2L15 reporters, we  amplified four 200bp fragments from the center 
of the peaks in BCL2L15 locus in and cloned  them into pTA-luc vector (Clontech). 
The genomic coordinates (human genome 18) of the fragments and the primers used 
for amplifications are as follows : 
Reporter 1:  
chr1: 114200350-114200550 
Primer 1 ACAGGTTTTTGCCATGTC 
Primer 2 ACTCTAAAAGTTAAGTTCAATAGTG 
 
Reporter 2:  
chr1: 114215750-114216950 
Primer 1 GAATTTCTCTTTGGTCCATG 
Primer 2 GACCACAGAAGGTGGTTA 
 
Reporter 3:  
chr1: 114218800-114219000 
Primer 1 AAACATTTTGCCAGAACCAT 
Primer 2 ATTTCCCCTTAAACTAGCAT 
 
Reporter 4:  
chr1: 114232100-114232300 
Primer 1 AAATGAGTAATCGCATTGTT 
Primer 2 AGTGTTATGCCTCCTTTTTG 
 
For luciferase assays, SW480 cells were cultured in 24-well-plates and transfected by 
using jetPEI transfection reagent (Polyplus Transfection) following manufacturer’s 
instruction. Renilla luciferase reporter CMV-RL (Norrmen et al., 2009) was co-
transfected for normalization. 48 h after the transfection cell were lysed and analyzed 
for luciferase activity using the Dual-LuciferaseTM kit (Promega). 
 
 
 
 
 
	  Statistical analyses 
Pairwise comparisons were performed by two-tailed Student’s t test. Recurrence of 
the metastases, lung colonization assay data, grouped analysis over time and other 
multiple populations analysis were analyzed through a Two-way ANOVA followed 
by Bonferroni post-tests. Multiple groups were analyzed over one variable with One-
way ANOVA (non parametric) with Bartlett’s test for equal variances and Tukey 
post-tests to compare each group independently. For overall survival analysis, the 
Kaplan-Meyer method was used. Similar results were obtained using the Log-rank 
(Mantel-Cox) test or the Gehan-Breslow-Wilcoxon test.  
 
Column or grouped analysis data were represented as vertical box & whiskers, where 
error whiskers had Tukey appearance; vertical mean and standard mean error (SEM) 
plus replicates; or histograms with vertical bars indicating the mean ± SEM. Each in 
vitro or 3D culture experiment was repeated at least twice independently. 
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